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“The only thing worse than being blind is having sight but no vision” 
- Helen Keller 
 
 
  
ABSTRACT 
Our vision is central to our quality of life enabling us to interact with our environment and 
lead productive lives. The ability to see begins in the retina, one of the paramount features of 
the eye, as it takes on the task of converting light signals to nerve impulses that are relayed to 
the visual centers of the brain. Proper functioning of the retina is essential for our visual 
experience. In this thesis, two different aspects of retinal dysfunction are highlighted together 
with potential therapeutic interventions. One of these is the childhood cancer retinoblastoma, 
which is characterized by uncontrolled cell proliferation after the loss of the RB1 gene. And, 
the other is retinal neurodegeneration which is characterized by the dysfunction and death of 
the retinal cells. We targeted the pyrimidine ribonucleotide synthesis pathway as a possible 
strategy to prevent retinoblastoma cell growth and to promote cell death. In the case of retinal 
neurodegeneration, we explored the neuroprotective effect of human neural progenitor cell 
(hNPC) derived neurotrophic factors to support retinal cell survival.   
The rationale to target pyrimidine ribonucleotide synthesis as a strategy to treat 
retinoblastoma cells was based on our findings in paper I. In this paper we discovered a 
novel dihydroorotate dehydrogenase (DHODH) inhibitor after screening a library of 
compounds for their ability to increase p53 transcription factor activity in two reporter cell 
lines, the ARN8 melanoma cell line and the T22 mouse fibroblasts. Amongst the hit 
compounds, we selected compound HZ00 because it was more active on the ARN8 cells than 
on the T22 fibroblasts and due to its favorable medicinal chemistry properties. Regarding the 
mechanism of action of HZ00 on the p53 pathway, we observed that it was able to induce p53 
synthesis without affecting p53 mRNA levels. Moreover, HZ00 was able to kill cancer cells 
and also synergize with an inhibitor of p53 degradation both in vitro and in vivo. During our 
studies on the identification of the target for HZ00, we observed that short treatment times 
with HZ00 caused ARN8 cells to accumulate in S phase and long treatments led to an 
increase in the proportion of cells in SubG1. Moreover, the supplementation with an excess 
of uridine was able to prevent the cell death effect. Based on these and other facts, we 
eventually narrowed down the target for HZ00 to DHODH, and confirmed this finding with 
enzymatic assays using purified DHODH. A further search for more potent analogues of 
HZ00 led to the identification of HZ05. HZ05 was able to accumulate a number of different 
cancer cells in S phase, which was followed by increase in SubG1 levels. However, the 
U2OS cell line had a higher propensity to accumulate in S phase. Further analysis showed an 
increase in p53 expression in the S phase cells. When we pretreated the U2OS cells with 
HZ05 followed by nutlin-3a, cell death was observed. This indicated that DHODH inhibitors 
could sensitize cancer cells to p53 degradation inhibitors by accumulating them in S phase 
with high p53 levels. 
Retinoblastoma is typically a TP53 wild-type tumor characterized by inactivation of the RB1 
gene. This deficiency leads to the loss of the cell cycle’s major G1-S checkpoint protein Rb. 
In paper I, we described that DHODH inhibitors can activate p53 and also cause cancer cells 
to accumulate in S phase, and that this is eventually followed by death. Since retinoblastoma 
cells already have a dysfunctional G1-S checkpoint, the use of DHODH inhibitors seemed 
like a rational approach to promote retinoblastoma cell death. In paper II, we investigated 
the potential of the DHODH inhibitor brequinar to reduce retinoblastoma cell growth and 
promote cell death, both as a single agent and in combination with a nucleoside transport 
inhibitor, dipyridamole. Similar to the effects seen in paper I, we saw that brequinar as a 
single agent was able to accumulate retinoblastoma cells in S phase and to an extent, also 
cause an increase in cell death. However, the response was slow and required a treatment 
time of 6 days. When we treated the retinoblastoma cells with a combination of brequinar and 
dipyridamole, the cells responded with an S phase accumulation as early as 24 hours after 
treatment, with most of them driven towards cell death with increasing time. This synergistic 
effect was also seen with other DHODH and nucleoside transport inhibitors. Moreover, the 
combination treatment was effective in the presence of uridine at physiologic plasma 
concentrations. Further investigation showed activation of caspases 3 and 7 as well as an 
increased expression of cleaved PARP-1, indicating the onset of apoptosis. Additionally, the 
treatment of a p53 mutant retinoblastoma cell line also responded to brequinar and the 
combination treatment, suggesting that targeting pyrimidine ribonucleotide synthesis could be 
an attractive strategy to eliminate both p53 wild-type and p53 mutant retinoblastoma cells. 
In paper III and IV, we investigated the neurodegenerative events in an in vivo and in vitro 
model of retinal neurodegeneration with an emphasis on photoreceptor degeneration, second 
order neuron remodeling and glia reactivity. Furthermore, in paper IV we assessed the 
neuroprotective potential of hNPC derived neurotrophic factors in porcine retinal explant 
cultures. In paper III, the in vivo pdgf-bret/ret mouse model showed severe vascular defects 
due to the detachment of pericytes from the vascular endothelium. Degenerative events were 
followed on postnatal day (P) 7, 10, 15 and 28. These events were quite evident at P15 and 
worsened by P28, and included photoreceptor cell death, shortening of the cone outer 
segments and synaptic disassembly in the outer plexiform layer (OPL). Rod bipolar cells 
underwent remodeling and the Müller cells showed increased expression of GFAP (glial 
fibrillary acidic protein). The microglia also changed to their reactive amoeboid-like 
phenotype. For the in vitro porcine retinal explant model in paper IV, photoreceptor death 
increased significantly by 3 days in vitro. This was associated to the loss of the cone outer 
segments, mislocalization of opsin and synaptic disassembly in the OPL. Furthermore, we 
observed a loss and remodeling of horizontal cells, as well as severe gliosis of the Müller 
cells. The hNPC cocultured explants were observed to maintain photoreceptor survival 
through preservation of the cone outer segments, better opsin trafficking and retaining 
synaptic integrity. However, Müller cell gliosis was only alleviated by a decreased density of 
GFAP immunoreactive Müller cells. Both the in vivo and in vitro model of neurodegeneration 
demonstrated the vulnerability of photoreceptors to different mechanisms of retinal injury. 
The hNPC derived neurotrophic factors had the potential to preserve photoreceptors in the 
porcine retinal explants, but were not able to completely eliminate Müller cell gliosis. 
 
  
PREFACE 
The retina is an amazing tissue that gives us the ability to see the world around us. It consists 
of one of the most complex yet extremely organized network of neurons and glia that allow 
us to see in light, dark, depth and motion throughout our lifetime. Looking into the 
proliferative side and the degenerative side of retinal dysfunction has made me highly 
appreciate the sensitive balance between the life and death of these neurons and the great 
impact they place in our ability to see. It is reassuring to know that there are many dedicated 
researchers who are always on an endless mission to find novel and effective therapies to 
treat such maladies. Having been part of a drug discovery project, I can understand all the 
hard work and painstaking efforts it takes for a team of researchers to identify a potential 
molecule or form of therapy that could one day eventually be used to improve the lives of 
patients.  
Having said this, I would like to highlight that thesis is a continuation of the licentiate thesis 
which was completed in 2016, but was not published. In the Swedish academic system, a 
licentiate thesis can be done half-way through a doctoral program and is similar in structure 
to the doctoral thesis. Major parts of the licentiate thesis have been included in the current 
thesis.  
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1 INTRODUCTION 
1.1 THE RETINA 
Sight is one of our most precious senses that helps us to perceive and interact with the 
environment around us. Our ability to see begins in our eyes where incoming light is focused 
on the retina, a thin neurosensory tissue that lines the back of the eye (1-3) (Fig 1A). The 
retina is part of the central nervous system and is responsible for the visual processing of 
photons to nerve impulses that are ultimately sent to the vision centers of the brain for 
interpretation. The retina achieves this task through the collective effort of its multiple 
neurons and glial cells that are morphologically arranged in a highly organized fashion. The 
remarkable complexity and efficiency of this neuronal circuitry together with its integration 
to the brain gives us our visual experience in the form of color, shade, motion and depth (2-
4).  
 
Figure 1. The human visual sense organ. (A) Diagram of the eye; an enlarged diagram of the fovea is shown in the box. The 
retina forms the inner lining of the most posterior part of the eye. The RPE is sandwiched between the retina and choroid, a 
vascularized and pigmented connective tissue. (B) Diagram of the organization of retinal cells. R, rod; C, cone; B, bipolar 
cell; H, horizontal cell; A, amacrine cell; G, ganglion cells; M, Müller cell; RPE, retinal pigment epithelium (C) A 
Richardson's methylene blue/azure II stained transverse section of human retina. The retina has laminated layers which 
include the outer nuclear layer (ONL), inner nuclear layer (INL) and ganglion cell layer (GCL), which are separated by the 
outer plexiform layer (OPL) and inner plexiform layer (IPL). Adjacent to the RPE lie the photoreceptor outer segments (OS), 
while the photoreceptor inner segments (IS) lie close to the ONL (4). Reproduced with permission from Rockefeller 
University Press all copyright retained (2010). 
1.1.1 Structural organization of the retina 
The vertebrate retina consists of a distinct laminated cytoarchitecture that is divided into 
neuronal and plexiform layers that contain the neuron cell bodies and synapses respectively 
(2-4) (Fig 1B and C). The neurons present in these different layers will be discussed in more 
detail in the next section. The first set of neurons in the outermost region of the retina are the 
light-sensitive photoreceptor cells. These include the rods, which mediate vision in dim light, 
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and the cones that allow us to see color in bright light. The cell bodies of the photoreceptors 
form the outer nuclear layer (ONL) of the retina, and their axon terminals form synapses with 
the bipolar cell dendrites and the horizontal cell processes. This synaptic layer is referred to 
as the outer plexiform layer (OPL). The OPL is followed by the inner nuclear layer (INL) that 
consists of the cell bodies of the second order neurons which include the bipolar, horizontal 
and amacrine cells. Signals are transmitted from the bipolar and amacrine cells through 
synapses with ganglion cell dendrites present in the inner plexiform layer (IPL). The ganglion 
cell bodies form the ganglion cell layer (GCL) and their axons collectively form the nerve 
fiber layer (NFL) which converge and exit the eye as the optic nerve (2-4).  
Considering retinal topography, the retina can be broadly divided into a central and peripheral 
region (1-4). The central part of the retina comprises of a circular region known as the macula 
lutea which is located about 3.5 mm temporal to the optic disc and is approximately 6 mm in 
diameter (2, 5). The macula lutea (Latin for ‘yellow spot’) is so called because of its 
yellowish hue which occurs due to the presence of the xanthophyll pigments lutein and 
zeaxanthin (1, 2, 5). These pigments are known to filter light of short wavelength (3, 5-7) and 
also serve as antioxidants (2, 3, 5, 7). Such properties help to decrease light scatter and 
prevent retinal damage due to photo-oxidation (2, 5-7). The centermost region of the macula 
contains an important anatomical feature called the fovea that is demarcated by a gentle 
depression in the retina and is 700 µm in diameter (1, 2, 4) (Fig 1A). Structural modifications 
in the fovea make it specially designed for high visual acuity. The cone photoreceptors are 
present in this region at one of the highest densities, reaching about 199,000 to 300,000/mm2 
(1, 2, 8). The depression in the structure is attributed to the lateral shifting of the inner regions 
of the retina such that light can directly reach the cones without interference from the other 
retinal layers. The absence of retinal vasculature in this region also directly exposes the cones 
to incident light. Additionally, the ratio of cones to ganglions cells in the fovea reaches 1:1, 
allowing us to see color images in great detail (1, 2, 4, 5).  
The peripheral retina starts at the boundary of the central retina and stretches to the ora serrata 
which marks the beginning of the ciliary body (1, 2, 5). This area of the retina is mainly 
responsible for our peripheral vision, which is more sensitive to movement detection rather 
than image resolution. This means that images appear less clear but the slightest change in 
motion is easily detected and usually attracts our eyes or head towards the motion. The cone 
density decreases the farther away we deviate from the fovea and the photoreceptor 
population becomes more rod dominant in the peripheral retina where rods outnumber cones 
20:1. The convergence from photoreceptors to ganglion cells is much higher in this region, all 
of which leads to greater spatial summation rather than spatial resolution (2, 5).  
It should be noted that the structure of the vertebrate retina can vary significantly between 
different species, and emphasis has been placed on the human retina in this thesis. 
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1.1.2 Cellular components of the retina and the visual pathway 
The major cellular components of the retina include the neurons, glial cells and retinal 
pigment epithelium (RPE). Among the neurons, the photoreceptors, bipolar cells and 
ganglion cells are responsible for the phototransduction of light while the horizontal and 
amacrine cells help in the modulation of neural signals. The glial cells provide support for the 
efficient functioning of these neurons and include the Müller cells, microglia and astrocytes. 
The RPE is a dark pigmented layer of epithelial cells that lies adjacent to the photoreceptors. 
It is known to perform a number of functions, some of which include the absorption of 
scattered light and the maintenance of photoreceptor health (1, 2). The morphology and 
function of these cellular components together with their association in the visual pathway are 
given in more detail below.  
1.1.2.1 First order neuron: Photoreceptors 
Photoreceptors are highly specialized neurons that are responsible for initiating the 
phototransduction cascade, which can be described as the process by which photons are 
converted to neuronal signals (1-4). As mentioned previously, photoreceptors are of two 
types, the rods and the cones. The human retina consists of rods and three different kinds of 
cones which can be distinguished by their sensitivities to different wavelengths of light. 
These include the long wavelength (L) cones that detect red, mid wavelength (M) cones that 
detect green and the short wavelength (S) cones that detect blue; thus, the human retina can 
be referred to as having trichromatic vision (1, 3, 9). Both rods and cones share similar 
structural features which comprise of an outer segment (OS), cilium, inner segment (IS), cell 
body, axon (also called inner fiber) and synaptic terminal (Fig 2). The OS is the light 
sensitive unit that is densely packed with membrane discs that enclose the photopigments 
rhodopsin and opsin, in rods and cones respectively. In rods, these membrane discs appear to 
float in the OS cytoplasm, whereas in cones they are continuous with the OS plasma 
membrane and form stacked invaginations. Upon continuous light irradiation in a high 
oxygen environment, the photoreceptors produce free radicals that damage the disc 
membranes (1, 4). This is compensated for by the regular renewal of the discs, where newly 
formed discs at the inner end of the OS gradually displace older ones outwards until they are 
sloughed off and phagocytosed by the RPE. The OS is connected to the IS of the 
photoreceptor by means of a physical bridge called the cilium. The IS contains numerous 
mitochondria in the ellipsoid region to meet the high metabolic demands of the 
photoreceptor, as well as necessary organelles in the myoid region for protein synthesis. 
Moving towards the more inner regions, the cell body contains the nucleus and this is 
followed by the axon that transmits the signals received from the outer parts of the cell to the 
synaptic terminal (1-4).  
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The synaptic terminals of the rods are called spherules and they have a small rounded pair-
like shape (Fig 2). Spherules have a deep invagination in their internal surface where usually 
two presynaptic ribbon units each form a synaptic complex with a pair of horizontal cell 
processes and one or more bipolar cell dendrites (2, 3, 10). Ribbons are special structures that 
are located perpendicular to the active zone of the synaptic membrane where neurotransmitter 
containing vesicles undergo exocytosis. The ribbon tethers a large number of these vesicles 
providing a reservoir of release-ready neurotransmitters which allow for high speed graded 
neurotransmission (11, 12). The presence of two ribbon synaptic complexes in the spherule 
and the deep invagination that houses postsynaptic processes close to the release site is 
thought to prevent rod signal spillover and the detection of single photons of light with high 
efficiency (10, 13). The cone synaptic terminals are called pedicles, and these are relatively 
larger than the spherules with broad flattened structures that have several superficial 
invaginations (Fig 2). Each of these invaginations contain a presynaptic ribbon that forms a 
synaptic complex in a similar fashion as the spherules, i.e. a pair of horizontal cell processes 
Figure 2. Structure of the rod and cone photoreceptors (1). Reproduced with permission 
from Springer Nature all copyright retained (2011). 
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and one or more bipolar cell dendrites (10, 14, 15). Cone pedicles also form basal junctions 
with bipolar cell dendrites at their flat bases. Additionally, they can also form gap junctions, 
which are reflective of electrical synapse transmission, with neighboring spherules and 
pedicles through projections that extend from their sides and bases, allowing crosstalk 
between the photoreceptors (15-18). Coupling between the cones is thought to reinforce 
signals and improve signal-to-noise ratio (13, 19). Whereas, coupling between cones and rods 
is thought to help detect intermediate light intensities by circumventing saturation at the rod 
synapses and providing an alternate route for the rod driven pathways (13, 20). 
The photopigments of the photoreceptor OSs are the first components to detect photons from 
incident light and initiate the phototransduction process. The photopigments are composed of 
a protein unit, i.e. the rod and cone opsins, which is covalently linked to a chromaphore 11-
cis-retinal (a derivative of vitamin A) (1-4, 21). Whereas the opsins can have different 
molecular structures (3, 22, 23), the chromaphore is the same in all mammalian 
photoreceptors (2). The spectral characteristics of the different opsins is based on their 
interactions with 11-cis-retinal making them photosensitive to specific wavelengths of light 
(21, 23). When photons reach the photopigments, it leads to the isomerization of 11-cis-
retinal to all-trans-retinal; the only light dependent step in the visual cascade. This event leads 
to a conformational change in the opsins, leading to the formation of a light activated opsin. 
This reacts with a G protein called transducin that contains GDP bound to its α-subunit. The 
interaction catalyzes the exchange of GDP for GTP, consequentially activating the α-subunit. 
This dissociates from transducin and activates phosphodiesterase by removing its two 
regulatory γ-subunits. In turn, phosphodiesterase hydrolyses cyclic GMP (cGMP) to 5 ̍- 
GMP. This decreases the levels of cGMP and results in the closing of cGMP-gated cation 
channels. Inhibition of the influx of cations across the plasma membrane causes the 
photoreceptors to hyperpolarize, i.e. the intracellular voltage becomes more negative, and 
inhibit neurotransmitter release from the synaptic terminals (1-4).  
In order for the next phototransduction cascade to take place, the photoreceptors must 
undergo a recovery phase where the activated photopigment is deactivated. This is 
accomplished by (a) phosphorylation of the activated photopigment followed by binding to 
arrestin, (b) inactivation of transducin and phosphodiesterase, and (c) restoration of cGMP by 
the action of guanylate cyclase.  Once the activated photopigment is deactivated, all-trans-
retinal is released from the opsin and then reduced to all-trans-retinol in the OS cytoplasm. 
This is then transported to the RPE to be isomerized to 11-cis-retinal. The 11-cis-retinal is 
transported back to the OS where it can reconjugate with the opsins to form photopigment. 
This process is known as the classical visual cycle, and usually refers to the rods (1, 3, 4, 23). 
In case of cones, the recycling of the chromophore can additionally occur in the Müller cells 
in order to rapidly supply chromaphore during sustained daylight vision; this is known as the 
cone visual cycle (2, 3, 23, 24). 
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1.1.2.2 Second order neurons: Bipolar, horizontal and amacrine cells 
The second order neurons include the bipolar, horizontal and amacrine cells. The bipolar cells 
provide a direct link for the photoreceptor signals to be transmitted to the ganglion cells 
through a forward or vertical pathway of neural transmission (1-4, 25). The horizontal and 
amacrine cells, mainly allow for the lateral communication and integration of signals in the 
OPL and IPL respectively. Bipolar cell dendrites branch in the OPL and form synapses with 
photoreceptors and horizontal cells, whereas their axons form synaptic bulbs in the IPL and 
synapse with amacrine and ganglion cells. They are known to exclusively contact either rods 
or cones and thus can be broadly classified as rod bipolar cells and cone bipolar cells. The rod 
bipolar cells can only transmit information obtained from the rods to the amacrine cells and 
rarely synapse with ganglion cells (1-3, 25). The amacrine cells then send these signals either 
directly to the ganglion cells or to the cone bipolar cells which in turn communicate with 
ganglion cells (1, 3). Such a synaptic arrangement helps to converge the rod and cone 
signaling pathways. In case of the cone pathway, the cone bipolar cells can directly transmit 
nerve signals from the cones to the ganglion cells. The bipolar cells can be divided further to 
ON or OFF subtypes depending on their electrophysiological characteristics. The ON bipolar 
cells are known to depolarize upon light stimulation whereas the OFF bipolar cells 
hyperpolarize. The rod bipolar cells are inherently of the ON type, while the cone bipolar 
cells can be ON or OFF (1-3, 25). 
The horizontal cells lie near the outer aspect of the INL with their axons and dendritic tufts 
lying parallel to the retinal surface and terminating in the OPL. These cells form synapses 
with photoreceptors and bipolar cells as well as gap junctions with other horizontal cells 
enabling lateral communication and integration of signals. They provide inhibitory feedback 
to photoreceptors and inhibitory feedforward to the bipolar cells (1-3, 26). These signaling 
patterns are thought to contribute to contrast enhancement and color opponency (1, 27, 28). In 
the human retina, the horizontal cells can be divided into three types: HI, HII and HIII (1, 2, 
29). The HI horizontal cell dendrites contact cones while its axon terminals contact rods. All 
the HII processes are only specific for cones possibly of the blue type, whereas the HIII 
contacts red/green cones and possibly rods (2, 29). 
Amacrine cells usually reside in the inner aspect of the INL with their processes, which have 
both dendritic and axon like characteristics, in the IPL (1-3, 30). In some cases, amacrine 
cells have also been found to be in the GCL and the IPL. Similar to the horizontal cells, the 
amacrine cells also enable lateral communication by forming synapses with bipolar cells and 
other amacrine cells. However, they can also have direct synaptic links with the ganglion 
cells. Due to the wide coverage of their processes they have an important role in modulating 
the signals transmitted to the GCL. There are about 30 to 40 different types of amacrine cells 
which can be classified into four groups according to the extent of coverage of their 
branching processes; these include narrow field, small field, medium field, and large field. 
Amongst the numerous types of amacrine cells, the narrow field A2 type has been well 
characterized. Its function has been related to the transferring of signals from the rod bipolar 
cells to the ganglion cells, or channeling the rod bipolar signals to ON cone bipolar cells by 
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means of gap junctions, or OFF cone bipolar cells through chemical synapses (2, 3, 30). 
Another wide field A17 cell is thought to modulate the rod bipolar signals before they are 
received by the A2 cells (2, 30).  
1.1.2.3 Third order neuron: Ganglion cell 
The ganglion cells are the third order neurons which are last to receive the nerve impulses. 
Their cell bodies lie in the GCL and their dendrites are localized to the IPL where they make 
contacts with the amacrine and bipolar cells. The axons bundle together to form the nerve 
fiber layer that ultimately exits the eye as the optic nerve (1-3, 13). About 90% of the 
ganglion cells send their transmissions to the lateral geniculate nucleus of the brain which 
processes visual information, and 10% to the supraoptic and subthalamic regions which are 
responsible for pupillary reflexes and circadian rhythm regulation (3). The presence of nearly 
20 different types of ganglion cells have been described in the human retina (1-3, 13). 
Interestingly, a sub-population of ganglion cells have been reported to contain the 
photopigment melanopsin, although it was generally considered that photopigments are only 
restricted to the photoreceptors. These cells are thought to participate in nonvisual processing 
tasks (3, 13, 31, 32). 
1.1.2.4 The retinal pigment epithelium 
The RPE is a single layer of postmitotic cuboidal epithelial cells that is located at the 
outermost part of the retina (1, 33) (Fig 1 and 2). Its basal aspect is adjacent to the Bruch’s 
membrane of the choroid whilst the apical aspect is oriented towards the photoreceptor OSs. 
The presence of the pigment melanin in these cells gives the RPE its name. Apart from 
absorbing light and preventing excess light scattering, the RPE plays a supportive role in 
maintaining the survival and functioning of the photoreceptors (1, 2, 33). As previously 
mentioned, it can phagocytose the shedding discs of the photoreceptor OSs, and with the help 
of its numerous lysosomes it can ingest almost 2000 discs on a daily basis (2). In conjunction 
to this, it plays an important role in the visual cycle by metabolizing, storing and transporting 
the chromophore required for the photosensitivity of the opsins. Its production of antioxidants 
helps to prevent cellular damage from free radicals that are generated due to its constant 
exposure to light, high oxygen environment as well as high metabolic activity. The RPE also 
has the ability to secrete a number of different growth factors like vascular endothelial growth 
factor (VEGF), pigment-epithelium derived factor (PEDF), platelet-derived growth factor 
(PDGF), insulin-like growth factor I (IGF-I), fibroblast growth factor (FGF) as well as many 
others that are thought to help maintain the photoreceptors and the choriocapillaris (1, 2, 33). 
Probably one of the most essential roles played by the RPE is its contribution to the formation 
of the blood-retinal barrier. In addition, the RPE also controls the selective movement of 
nutrients and metabolites from the choriocapillaris to the retina and the removal of waste 
products from the retina to the choriocapillaris. This is achieved by the presence of tight 
intracellular junctional complexes and facilitated transport mechanisms for ions and 
molecules (1, 2, 33-35).   
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1.1.2.5 Glial cells: Müller cells, astrocytes and microglia 
The human retina consists of three types of glial cells which include the Müller cells, 
astrocytes and microglia. The Müller cells are the principle glia of the retina. They radially 
span the entire expanse of the neural retina with their cell bodies residing in the INL and 
processes ensheathing retinal neurons, blood vessels and the ganglion cell axons. Their basal 
extensions flatten and expand to form the endfeet that contribute to the formation of the inner 
limiting membrane. Their apical processes terminate near the photoreceptor ISs where they 
form a series of junctional complexes that appear to make a membrane which is referred to as 
the outer limiting membrane (1-3). Besides giving structure, the Müller cells are known to 
provide a number of beneficial functions that help maintain the health, homeostasis and 
functionality of the retina. Amongst these include maintaining ion balance; maintaining the 
pH of the extracellular space; recycling neurotransmitters; recycling chromophores for the 
cone opsins in the cone visual pathway; producing antioxidants, cytokines and growth 
factors; providing a source of glucose by storing glycogen and helping to maintain the blood-
retinal barrier (1, 2, 36, 37). They are also referred to as living optical fibers because they can 
guide light through the inner retinal layers and help reduce light scatter (36, 37).  
The astrocytes are star shaped cells that are found surrounding the NFL, GCL and superficial 
retinal vasculature. They are thought to migrate from the optic nerve and enter the retina to 
help in the development of the retinal vasculature. By ensheathing the glial cell axons they 
help to form axon bundles of the nerve fiber layer. Amongst their other supportive roles 
include neurotrophic support, supplying metabolites like glucose, taking up K+ and 
neurotransmitters from the extracellular space and maintenance of the blood-retinal barrier (2, 
37).  
The microglia are important for the retina’s defense mechanism in case of pathological 
events. They are phagocytic cells that are usually located in the inner layers of the retina. 
They have two morphological phenotypes that determine their immune status. In case of a 
ramified morphology they are in a resting state and perform surveillance of the surrounding 
tissue with their processes. When they change to an amoeboid morphology they are said to be 
in an activated state ready to perform their phagocytic function. Apart from this, the microglia 
may also secrete cytokines and neurotrophic factors in response to certain stimuli, help to 
remodel neuronal circuits as well as remove cell debris and damaged synapses (37-39).     
 
1.1.3 Development of the retina   
The nervous system originates from the ectodermal neural plate. During embryogenesis, this 
plate is rolled up in the midline of the embryo to form the neural tube. The retina originates 
from the neuroepithelium of the anterior neural tube that evaginates to form the optic 
vesicles. During this process, the optical vesicles remain in contact with the neural tube by 
means of the optic stalk. At the next stage, the optic vesicle invaginates to form a double 
layered structure called the optic cup. The inner layer of the optic cup transforms into the 
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neural retina and the outer layer forms the RPE. While the optic cup forms, the optic stalk is 
reduced to a narrow bridge of cells that provides the scaffold to form the optic nerve (3, 40). 
During the morphological transformation of the optic vesicle to the optic cup, the neuroblasts 
that make up the inner layer already start to proliferate. They have the potential to 
differentiate into all types of cells of the neural retina as well as the Müller glia. During 
proliferation, their nuclei repeatedly migrate from the outer to the inner regions of the retina 
to form a pseudostratified epithelium. Once the cells cease to divide, they differentiate and 
migrate to their final destinations. The first neuron born is the ganglion cell, followed by the 
cone, amacrine and horizontal cells, and then the rod and bipolar cells. The Müller cell is the 
last to differentiate. At around the same time, the cells of the outer wall of the optic cup 
proliferate in a single plane to give rise to the RPE (3, 40). The determination of cell fate 
during retinal development is dependent on a number of extrinsic and intrinsic factors as well 
as the response of the multipotent progenitors to spatial and temporal cues. These could 
involve transcription factors and growth factors that have regulatory roles in cell cycle or cell 
migration (3, 41).  
Another important aspect during retinal development involves programmed cell death or 
apoptosis as a physiological process during development. In the retina, it has been shown that 
apoptosis can take place at an early phase during neurogenesis, cell migration and cell 
differentiation, as well as at a later phase when connections and synapses are already 
established, allowing for the selective elimination of aberrant neuronal wiring. These events 
help to fine tune the retina such that it can provide optimal performance (42). Some of the 
factors that may regulate apoptosis include the availability of neurotrophic factors, the 
interaction of neuron neurites with glia, and microRNAs (42, 43).  
 
1.1.4 Vascular system of the retina 
The mature retina is a highly metabolically active tissue that has one of the highest oxygen 
demands in the body (44). This demand is met by the formation of two independent vascular 
networks, which includes the choroid and the retinal vasculature. During the embryonic 
stages of eye development, the oxygen requirements are fulfilled by the choroidal vessels as 
well as a transient vascular system referred to as the hyaloid system. The hyaloid system 
forms a dense intraocular circulatory system that in later stages of development regresses as 
the retina matures. While the hyaloid vessels regress, a vascular plexus emerges from the 
optic nerve head, which later matures to form the retinal vasculature that supports the inner 
retinal layers (1, 44, 45). The transition from the hyaloid system to the retinal vasculature is 
thought to occur around mid-gestation for humans (45). The vascular plexus, which 
originates from the central retinal artery, expands towards the peripheral regions of the retina 
through biochemical cues received from the astrocytes. The astrocytes emerge in the retina 
before the formation of the retinal vasculature and are thought to form an astrocyte cellular 
network in the inner retina that act as a template for the development of these vessels. Just 
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before vascular development the astrocytes express VEGF, which is a primary growth factor 
for angiogenesis and endothelial cell survival. The differentiating retina and its continuous 
increase in metabolic activities creates a hypoxic environment, which triggers the expression 
of VEGF from the astrocytes. Sprouting endothelial tip cells of the vascular plexus respond to 
VEGF and undergo an angiogenic response. Once the primary vascular plexus reaches the 
margins of the retina travelling along the nerve fiber layer, angiogenic sprouts from the veins, 
venules and capillaries start to innervate the inner layers of the retina perpendicular to the 
plexus along the processes of the Müller cells in response to VEGF secreted by the Müller 
cells and somatas in the INL. Once the sprouts reach the inner and outer borders of the INL 
they change their direction sideways to form two additional vascular networks that are 
oriented parallel to the primary vascular plexus. At this stage, the vessels in the nerve fiber 
layer are referred to as the superficial capillary network and those reaching the INL and its 
borders the deep capillary network (1, 2, 44-46).  
Once the inner retinal layers are vascularized, the vessels undergo further remodeling and 
maturation. Endothelial cells may be relocalized and strengthened whilst others may be 
removed by apoptosis in a process known as vessel pruning. During the sprouting and 
remodeling of the vessels, endothelial cells recruit pericytes by secreting PDGF-B which in 
turn interact with PDGF receptor β on the pericytes. Pericytes are known to promote vessel 
survival, maturation and stabilization by means of paracrine signaling and physical contact 
with the endothelial cells. Pericytes can signal endothelial cells by their secretion of 
angiopoietin 1 which binds to the Tie2 receptors on endothelial cells. Tight junctions like the 
zonula occludens hold the endothelial cells tightly together making the vessels unfenestrated. 
The involvement of tight junctions, pericytes and the glial cells help form the blood-retinal 
barrier in the retinal vasculature. The outer region of the retina remains avascular and is 
supported by the choroidal blood supply (2, 44, 45, 47).  
In humans, the development of the choroid completes by 22 weeks of gestation. The choroid 
provides oxygen and nutrition to the early retina by means of diffusion. It is known to branch 
into a dense network of capillaries, called the choriocapillaris, separated from the RPE by 
Bruch’s membrane (1, 2, 46). The generation of the choroid and its choriocapillaris is thought 
to be closely linked to the RPE. During choriocapillaris development the RPE highly 
expresses VEGF. It is thought that the secretion of angiogenic factors from the RPE promote 
choroidal development and differentiation (44). Unlike the retinal vasculature, the 
choriocapillaris is fenestrated and permeable allowing large molecules to easily escape and 
pass Bruch’s membrane. However, the blood-retinal barrier formed by the tight junctions in 
the RPE prevent entry of unwanted molecules to the retina (1-3). 
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1.2 RETINAL TUMORIGENESIS 
The development of the retina is a highly controlled process, however, certain genetic 
anomalies can lead to uncontrolled cell division causing retinal tumorigenesis and cancer, as 
is seen in the case of the childhood cancer retinoblastoma. Before going into more depth 
about retinoblastoma, it is important to have an understanding of cancer and its underlying 
mechanisms.   
1.2.1 Tumorigenesis and cancer 
Tumorigenesis can be defined as a multistep process that drives the transformation of normal 
cells to cancerous derivatives. This transformation is linked to the occurrence of a succession 
of genetic alterations that confer growth advantage to affected cells (48, 49). This means that 
the cell will lose its ability to regulate the cell cycle and start to divide uncontrollably. The 
underlying characteristics that permit this state of immortality can be understood by the well 
summarized work of Hanahan and Weinberg in the year 2000 as the 6 hallmarks of cancer 
(50), which they later expanded to 10 hallmarks in 2011 based on emerging research in the 
field (49). These include: genomic instability and mutation, inducing angiogenesis, activating 
invasion and metastasis, enabling replicative immortality, evading growth suppressors, 
sustaining proliferative signaling, evading cell death, deregulating cellular energetics, 
avoiding immune destruction and tumor-promoting inflammation (49, 50) (Fig 3).  
1.2.1.1 Causes of cancer 
According to the WHO, cancer is the second leading cause of death with approximately 9.6 
million deaths in 2018; the most frequently occurring types include lung, prostate, colorectal, 
stomach, liver, breast, cervical and thyroid cancers. The cause of cancer can be related to a 
large number of factors, which could be genetic or environmental in nature. Cancers that 
Figure 3. The hallmarks of cancer (49). Reproduced with permission from Elsevier all copyright retained (2011). 
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develop due to germline mutations usually occur early in life; some of these include Li-
fraumeni syndrome (TP53) (51), retinoblastoma (RB1) (52) and hereditary breast cancer 
(BRCA1 and BRCA2) (53). Environmental factors that are associated to cancer can be 
biological, physical or chemical in nature. Biological factors may be related to viruses like 
human papilloma virus (HPV) or hepatitis C and B, which has been linked to cervical cancer 
(54) and liver cancer respectively (55). Physical factors like UV radiation has been shown to 
increase risk of skin cancer (56), and asbestos exposure is directly linked to development of 
mesothelioma (57). Both natural and synthetic chemicals can also increase cancer risk (58). 
As for example, aflatoxin produced by certain Aspergillus molds can cause liver cancer when 
ingested or lung cancer when inhaled (58, 59).  
1.2.1.2 Current treatment strategies for cancer 
The current treatment strategies for cancer include conventional chemotherapy, radiotherapy 
and surgery. Conventional chemotherapeutic agents cause cell death by interfering with DNA 
or interacting with key proteins that participate in cell division. These drugs can be classified 
as DNA alkylating agents (e.g. cisplatin, carboplatin), DNA intercalating agents (e.g. 
doxorubicin), topoisomerase inhibitors (e.g. etoposide, topotecan), tubulin binding drugs (e.g. 
vincristine, paclitaxel) and anti-metabolites (e.g. gemcitabine, methotrexate). These agents 
are not specific and can target both cancer and normally dividing cells. As a consequence, 
there are significant toxicities associated, which include thrombocytopenia, 
myelosuppression, anemia, mucous membrane ulceration and alopecia. Moreover, these 
agents may also have genotoxic effects and cause secondary tumors after therapy; and the 
possibility of introducing further mutations is quite high, leading to more resistant or 
aggressive cancers (60). For example, leukemia was reported to develop in patients with 
colon adenocarcinoma (61), osteosarcoma (62) and bladder cancer (63) as a second 
malignancy after chemotherapy. Radiotherapy is the use of ionizing radiation to kill cancer 
cells. Similar to chemotherapy, it is not specific and does not discriminate between normal 
and cancerous cells. Even though it has a more localized treatment approach where only 
tumor sites are targeted, there are still reports of second malignancies among patients (64, 
65). Surgery is usually a better option, considering the side effects of these two forms of 
therapy, however, only tumors localized near non-vital organs can be removed.  
Targeted therapy is another option that involves a direct approach of killing specific types of 
cancers with small molecule drugs or antibodies that target one or more key cellular 
mechanisms. This approach is based on a thorough understanding of cancer pathways. 
Examples include erlotinib, that targets epidermal growth factor receptor in non-small cell 
lung cancer, and vemurafenib that inhibits the B-Raf serine/threonine protein kinase for 
melanoma (66). More recent therapeutic approaches involve immunotherapy, which is an 
indirect approach where the patient’s immune cells can be activated to kill the cancer, by the 
use of cytokines, antibodies, cancer vaccines or the more novel modified T cell therapies (e.g. 
CAR-T) (67). Although these therapies are promising, the problem of developing resistance 
and possible cancer relapse, as well as acquired toxicity in case of immunotherapy, are still 
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concerns. One way to overcome this is by employing combination therapies that target two 
different mechanisms to obtain synergistic or additive outcomes which can kill cancer cells 
with reduced risk of developing resistance (68, 69).  
 
1.2.2 Tumor suppressors and oncogenes 
As mentioned previously, cancer involves genetic alterations that lead to uncontrollable cell 
proliferation. These alterations mainly occur in genes that encode for proteins that help 
regulate cell growth and division, and include both tumor suppressor genes and oncogenes 
(70, 71).  
1.2.2.1 Oncogenes 
Proto-oncogenes encode for proteins that stimulate cell cycle progression and cell growth 
under normal physiological conditions. When proto-oncogenes are activated by mutations, 
amplifications or chromosomal rearrangements, they are referred to as oncogenes (72). The 
products of oncogenes can be divided into six groups: (a) transcription factors (e.g. MYC), 
(b) chromatin remodelers (e.g. ALL1), (c) growth factors (e.g. PDGF), (d) growth factor 
receptors (e.g. EGFR), (e) signal transducers (e.g. RAS, PI3K, AKT), and (f) anti-apoptotic 
proteins (e.g. BCL-2). Contrary to tumor suppressor genes, oncogenes undergo sustained 
activation which leads to uncontrolled hyperproliferation of cells (71, 72).  
1.2.2.2 Tumor suppressor genes 
As its name implies, tumor suppressor genes help to inhibit the formation of tumors. They 
encode for proteins that can be functionally categorized into five broad classes: (a) proteins 
that control cell cycle progression (e.g. Rb, p16) (b) receptors or signal transducers that 
prevent cell proliferation (e.g. TGF-β, APC), (c) checkpoint control proteins that trigger cell 
cycle arrest in response to chromosomal defects (e.g. p53, BRCA1, p16, p14ARF), (d) proteins 
that induce apoptosis (e.g. p53), and (e) proteins involved in DNA repair (e.g. p53, BRCA1) 
(73-75). In order for cancer to develop, tumor suppressor genes must undergo what is known 
as Knudson’s ‘two-hits’, where not one but both alleles need to be inactivated. In case one 
allele remains wild-type, it can still encode for the protein to carry out its functions (70, 73). 
However, there are exceptions to this rule; as for example, in case of p27 it has been seen that 
the remaining wild-type allele is insufficient to perform tumor suppression activity 
independently (76). Apart from these, cancer cells can also inactivate tumor suppressor genes 
through epigenetic silencing, and their encoded proteins by ubiquitin-proteasome 
degradation, overexpression of E3 ligases as well as protein mislocalization (73). 
Two important tumor suppressor proteins that have emphasis in this thesis are described 
below. 
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1.2.2.3 The tumor suppressor protein p53 
The tumor suppressor gene TP53 encodes for the protein p53. p53 mainly acts as a tightly 
regulated transcription factor which becomes activated in response to cellular stresses such as 
oncogene activation, nutrient deprivation, DNA damage and hypoxia. In response to these 
stimuli, it mediates a number of cellular responses including cycle arrest, DNA damage 
repair, apoptosis or senescence (77-79). Additionally, p53 can also cause apoptosis through 
its transcription factor-independent role as a pro-apoptotic BH3 (Bcl-2 homology domain 3) 
like factor (80). Hence, the function of p53 is paramount in ensuring the prevention of 
unregulated cell proliferation which could lead to tumorigenesis. Due to playing such a 
central role in cancer, p53 has been referred to as ‘the guardian of the genome’ (81). In 
agreement with its tumor suppressive role, TP53 mutation is quite frequent in many cancers; 
and in cases where the gene is intact, usually the p53 signaling pathway is inactivated by 
alterations in upstream regulators (77-79). 
In absence of stress signals, p53 is maintained at low basal levels by its negative regulator 
MDM2 (murine double minute 2, or HDM2 in case of humans), which is an E3 ubiquitin 
ligase. High cellular levels of MDM2 poly-ubiquitinates p53 for proteasomal degradation, 
whereas, low levels of MDM2 cause mono-ubiquitination of p53, and its nuclear export (77, 
82). These two proteins follow a negative-feedback loop where p53 can also transactivate 
MDM2 expression and maintain the cellular levels of its negative regulator. MDM2 is a weak 
E3 ligase, and its dimerization with a structurally related protein, MDMX (also known as 
MDM4, or HDMX in case of humans), is thought to enhance its ubiquitination activity. A 
positive regulator of p53, p14ARF, is also a tumor suppressor that interacts with MDM2 to 
prevent p53 degradation and stabilize it. In tumors where TP53 is not mutated, usually the 
p53 pathway is inactivated through increased expression of MDM2 and MDMX and deletion 
or epigenetic inactivation of the positive regulator p14ARF (77-79). 
As mentioned earlier, p53 can be activated in response to cellular stress. This leads to the 
transcription of a number of downstream genes. Some of these targeted genes, related to cell 
cycle arrest, DNA repair and apoptosis, are highlighted. 
Cell cycle arrest: One of the primary aspects of p53 activation is the inhibition of cell division 
by causing cell cycle arrest. One of the most well studied way that this is achieved is through 
stimulating the expression of p21Waf1/Cif1, which, among its many other roles, is a cyclin-
dependent kinase (CDK) inhibitor. CDKs form complexes with cyclin proteins to allow 
transition through the cell cycle. p21 is known to inhibit CDK1 and CDK2, which in turn 
results in cell cycle arrest and/or senescence (77, 79, 83). Apart from this, p21 can also 
prevent cell cycle progression by binding to proliferating cell nuclear antigen (PCNA) which 
is known to participate in DNA repair and replication. This interaction prevents DNA 
synthesis and, thus, arrests the cell cycle (83). p53 has also been reported to prevent G2/M 
transition by mediating transcriptional repression of cyclin B1 through the Sp1 transcription 
factor (84). 
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Genomic stability and DNA repair: p53 activation can help to maintain genomic stability by 
aiding its repair in case of damage. It can do this by targeting the expression of growth arrest 
and DNA damage inducible protein 45 (GADD45). GADD45 plays an important role in 
global genomic repair, as well as in DNA excision repair through interaction with PCNA (77, 
85).  
Apoptosis: In some cases, p53 may need to mediate cell apoptosis when cell damage is 
beyond repair. As a result, it is known to initiate the transcription of several pro-apoptotic 
factors, some of which include Bcl-2-associated X protein (BAX), p53 upregulated 
modulator of apoptosis (PUMA) and NOXA (77). 
It is comprehensible that the loss of p53 activity would prove detrimental to normal 
physiological functions. Since approximately 50% of cancers still harbor wild-type p53, 
pharmacological interventions have been used to reactivate the p53 pathway (86). 
Considering the diverse signaling cascades in the p53 network, many strategies can be 
employed to activate p53. Some of these involve inhibiting the interaction of MDM2/MDMX 
with p53; as for example, small molecules and stapled-peptides that competitively bind to 
MDM2 and prevent p53 degradation (e.g. nutlin-3, SAH-p53) (87, 88). Other molecules, like 
leptomycin B, can prevent the nuclear export of p53.  
Although 50% of cancers retain wild-type p53, we cannot ignore the fact that the other 50% 
have p53 mutations. The most frequently occurring mutations are missense mutations that 
usually occur in the p53 DNA binding domain. Drugs targeting p53 mutant cancers usually 
aim to restore p53 function (89). One such molecule is PRIMA-1 which can covalently 
modify the thiol groups in the mutant p53 DNA binding domain and help restore the protein’s 
conformation (89, 90). Another molecule, ZMC1 is believed to reactivate the R175H p53 
mutant by chelating zinc. It has been reported that defective zinc binding can destabilize the 
structure of the p53 protein and affect its transcriptional activity. ZMC1 is able to provide 
zinc to the mutant protein and help regain its structural integrity (89, 91). 
1.2.2.4 The tumor suppressor protein Rb 
The tumor suppressor gene RB1 encodes for the protein Rb. Rb was one of the first tumor 
suppressors to be identified. It is known to negatively control the cell cycle by regulating the 
G1/S checkpoint and blocking entry into S phase. Rb belongs to the family of pocket proteins 
which include p107 and Rb2/p130. All of these proteins have a binding region, termed as a 
‘pocket’, for E2F transcription factors. E2F transcription factors activate genes that are 
responsible for cell cycle regulation, DNA replication, DNA repair, apoptosis, and other key 
regulatory functions (92). During the cell cycle, Rb undergoes phosphorylation by CDK 2, 4 
and 6 which determines its physical interaction with E2F (93, 94). In absence of growth 
stimuli, Rb remains active in a hypo-phosphorylated state that is bound to E2F; this prevents 
E2F from activating genes necessary for S phase entry. However, when there is a growth 
signal CDKs phosphorylate Rb, which causes it to unbind from E2F, allowing E2F to 
perform its transcriptional activities so that the cell can progress through to the S phase (94). 
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The tumor suppressing activities of Rb, however, are not only due to its well-known 
regulation of the cell cycle. Rb is also known to promote cell differentiation by enforcing cell 
cycle exit. In case of neuronal differentiation, Rb sequesters a protein, ID2, which is known 
to inhibit basic helix-loop-helix transcription factors that are important for differentiation 
(95). Rb can also induce the transcriptional activities of C/EBP proteins, which participate in 
the terminal differentiation of a variety of tissues, like adipocytes (96) and leukocytes (97). 
Apart from this, Rb is also known to play important roles in the maintenance of chromosome 
stability, and the repression of genes through chromatin remodeling (93, 94). 
The inactivating RB1 mutation is usually seen in a few types of cancers, which include 
retinoblastoma (more details in next section) and small cell lung cancer. However, the Rb 
pathway is usually disrupted in most cancers, some of which could be due to 
hyperphosphorylation (98), viral oncoprotein binding (99) or methylation of the RB1 gene 
that prevents its transcription (100). Some of the therapeutic interventions currently used and 
under investigation for retinoblastoma treatment are mentioned in the next section. 
 
1.2.3 Retinoblastoma 
Retinoblastoma is a pediatric intraocular tumor that originates during retinal development in 
young children, with an incidence of approximately 9000 new cases per year globally (101, 
102). Although quite rare, it accounts for the most common form of eye cancer in children 
(102, 103). The disease burden is quite high in developing nations where the mortality rate is 
40 -70%, compared to 3-5% for developed nations. Due to the young age of patients and 
modest symptoms, retinoblastoma cases are usually left undiagnosed until late stage of tumor 
development. The initial signs of retinoblastoma are leukocoria (a white reflex visible 
through the pupil) and strabismus (misaligned eyes). Lack of awareness of these signs, poor 
socioeconomic conditions and limited access to healthcare are thought to contribute to the 
higher mortality in developing nations (102, 104). 
1.2.3.1 Genetic basis of retinoblastoma 
Retinoblastoma was the first model used to establish Alfred Knudson’s two-hit hypotheses 
for tumorigenesis, which states that both alleles of a tumor suppressor must be lost in order 
for cancer to develop (105). Retinoblastoma occurs due to the biallelic inactivation of the 
RB1 tumor suppressor gene. In case of sporadic retinoblastoma, one retinal cell must undergo 
two mutations (hits), i.e. loss of both the wild-type alleles for RB1 (Fig 4). In case of a 
germline mutation, a retinal cell would need just one more ‘hit’ to lose the wild type allele.  
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Usually patients with sporadic retinoblastoma have the disease in only one eye (unilateral), 
whereas patients with germline mutation tend to have the disease in both their eyes (bilateral). 
Numerous types of mutations have been reported for the RB1 gene, which include missense, 
nonsense, splicing mutation, frameshifts, microdeletions, macrodeletions and promoter 
methylation (106). Intriguingly, some sporadic retinoblastomas arise in absence of RB1 loss, 
and are instead driven by the amplification of the NMYC oncogene (107) (Fig 4). Although 
RB1 loss poses a risk for malignancy, it only initiates tumor development with the formation 
of a retinoma, which is the benign form of retinoblastoma. Further genomic changes are 
required for the tumor to progress to the highly invasive form of the cancer. This is usually 
referred to as the additional hits required for retinoblastoma development from a retinoma 
(108) (Fig 4). These can be characterized as distinct patterns of genomic gains and losses, 
with gains at 1q, 2p and 6p, and loss at 16q chromosomal sites. The genes affected in these 
regions which are thought to participate in disease progression include KIF14 (kinesin family 
member 14) and MDMX on 1q, NMYC on 2p as well as DEK (DNA‐binding proto‐oncogene) 
and E2F3 transcription factor on 6p. Losses at 16q include CDH11 (cadherin‐11) and RBL2 
(also called p130). Among these genes, amplification of MDMX has been related to blocking 
the p53 pathway in retinoblastoma, which otherwise has an intact p53 gene (109, 110). 
1.2.3.2 Current treatment strategies 
Treatments that are currently used for retinoblastoma include focal therapy, chemotherapy, 
external beam radiotherapy (EBRT) and enucleation (surgical removal of the eye). Usually, 
one or a combination of these treatment strategies are employed based on tumor laterality and 
disease stage as shown in table 1 (110). Focal therapy is used to locally treat small tumors in 
cases where there is no vitreous seeding. These include photocoagulation, cryotherapy, 
thermotherapy and brachytherapy (110, 111). Photocoagulation employs the use of a diode 
laser, cryotherapy uses freeze-thaw cycles, thermotherapy uses infra-red, ultrasound or 
microwaves and brachytherapy uses radiation with custom designed plaques (111). Larger 
tumors are treated with chemotherapy to reduce tumor size usually using three classes of 
drugs: DNA alkylating agents (e.g. cisplatin, carboplatin), topoisomerase II inhibitors (e.g. 
etoposide, teniposide), and tubulin polymerization inhibitors (e.g. vincristine). The common 
Figure 4. Retinoblastoma genetics. The cancer can initiate with a germline RB1 mutation followed by a single somatic 
hit, or with two somatic mutations (M1 and M2). Loss of RB1 leads to the benign retinoma; further mutations (M3 to 
Mn) are required for malignancy. Retinoblastoma can also initiate by amplification of MYCN, with other genomic 
changes as yet unknown (104). Reproduced with permission from John Wiley and Sons all copyright retained (2018). 
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combination of selected agents used in the clinic include vincristine, etoposide, and 
carboplatin. Usually chemoreduction is used together with focal therapies. EBRT is no longer 
used due to the risk of developing secondary malignances, however, exceptions may be made 
when other treatment options do not yield satisfactory results (103, 110). Enucleation is based 
on whether a patient has unilateral or bilateral retinoblastoma. To avoid the risk of disease 
dissemination, patients with unilateral retinoblastoma usually undergo enucleation. However, 
in case of bilateral patients, the worst affected eye is enucleated and the remaining eye is 
salvaged so that the child can at least retain vision (103, 110, 111).  
Table 1: The choice of chemotherapy based on tumor laterality and disease stage (110). Reproduced with 
permission from Bentham Science Publishers Ltd. all copyright retained (2016). 
Group Globe Salvage 
Likelihood 
Quick 
Reference 
Specific Clinical Characteristics Treatment 
A Very Favorable 
(good visual and 
overall prognosis) 
Small tumors 
away from 
fovea and disc 
Tumors ≤ 3 mm in greatest 
dimension confined to the retina, 
and 
Located at least 3 mm from the 
foveola and 1.5 mm from the optic 
disc 
Argon-YAG laser 
Diode laser-induced hyperthermia 
Cryotherapy 
Brachytherapy 
B Favorable 
(good visual 
prognosis) 
Larger tumor All remaining tumors confined to 
the retina not in Group A 
Subretinal fluid (without subretinal 
seeding) ≤ 3 mm from the base of 
the tumor 
VCR + low dose CBP 
Focal therapy for 2-5 cycles 
C Doubtful 
(visual prognosis 
variable) 
Localized 
seeding 
Local subretinal fluid alone > 3 to 
≤ 6 mm from the tumor 
Vitreous seeding or subretinal 
seeding ≤ 3 mm from the tumor 
VCR + high dose CBP + ETO + 
G-CSF, up to 6 cycles 
Focal therapy 
Possible local carboplatin 
D Unfavorable 
(high morbidity 
from treatment, 
visual prognosis 
variable) 
Diffuse seeding Subretinal fluid alone > 6 mm from 
the tumor 
Vitreous seeding or subretinal 
seeding > 3 mm from the tumor 
VCR + high dose CBP + ETO + 
G-CSF, up to 6 cycles 
EBRT 
Possible local carboplatin 
E Very unfavorable 
(high morbidity 
from treatment, no 
visual potential) 
Extensive Presence of one or more of the 
following poor prognosis features: 
   - More than 2/3 globe filled with 
tumor 
   - Tumor in anterior segment 
   - Tumor in or on the ciliary body 
   - Iris neovascularization 
   - Neovascular glaucoma 
   - Opaque media from hemorrhage 
   - Tumor necrosis with aseptic 
orbital cellulitis 
   - Phthisis bulbi 
Enucleation 
Prophylactic 3-agent 
chemotherapy if high-risk features 
for disease dissemination 
observed on consensus pathologic 
evaluation 
Abbreviations: CBP = carboplatin, EBRT = external beam radiation therapy, ETO = etoposide, G-CSF = granulocyte colony-stimulating factor, PD = 
progressive disease, VCR = vincristine 
Although these current treatment regimens have been used successfully to treat many 
retinoblastoma patients, they are not devoid of side effects. Focal treatments may increase the 
chance of vitreous seeding, vascular occlusion, retinal fibrosis, traction, retinal tears and 
detachment, proliferative vitreoretinopathy, chorioretinal atrophy and cataracts (110, 111). 
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Brachytherapy can lead to radiation-induced retinopathy and optic neuropathy. 
Chemotherapy, comes with a myriad of adverse effects whether given systemically or intra-
arterially. Systemic administration can lead to neurotoxicity, nephrotoxicity, hyponatremia, 
ototoxicity, nephrotoxicity and secondary leukemia; whereas intra-arterial administration 
leads to vitreous hemorrhage, myositis, eyelid edema, microemboli to the retina and choroid, 
orbital congestion, dysmotility, choroidal atrophy, ophthalmic artery stenosis, optic atrophy, 
and branch-retinal artery occlusion which could lead to blindness (111). Enucleation means 
the loss of an eye, which comes with cosmetic defects and partial vision loss (110, 112).  
Due to the numerous side effects and possible complications of the current treatments, there 
is a need for safe and more effective alternatives. Efforts are being made at investigating new 
treatment modalities for retinoblastoma. RB1 gene replacement therapies are under 
investigation, however, there are still challenges considering the unpredictable effects of gene 
dosage and gene delivery strategies (94, 113). Other interventions involve the use of small 
molecule drugs. Some of these include reactivation of the p53 pathway by inhibiting MDMX 
(109), and targeting E2F1 transcription factor activity by blocking histone deacetylases 
(HDAC) (114). 
 
1.3 PYRIMIDINE RIBONUCLEOTIDES 
Pyrimidine ribonucleotides are primarily known as the building blocks for RNA and as the 
precursors for the pyrimidine deoxynucleotides for the synthesis of DNA. The pyrimidine 
bases uracil, cytosine and thymine are composed of heterocyclic, six-membered, nitrogen-
containing carbon ring structures. These are bound to ribose to form nucleosides uridine, 
thymidine and cytidine, respectively. Phosphorylation of these nucleosides gives rise to 
monophosphate, diphosphate and triphosphate pyrimidine ribonucleotides. Apart from being 
the precursors of nucleic acids, pyrimidine ribonucleotides play essential roles in various 
biosynthetic processes involved in cell growth and metabolism. Among these are the 
synthesis of cell membrane phospholipids and polysaccharides, glycosylation of proteins and 
lipids, as well as glucuronidation in detoxification processes (115).  
1.3.1 Pyrimidine ribonucleotide synthesis pathways 
Pyrimidine ribonucleotides can be synthesized through the de novo or the salvage pathways. 
In de novo synthesis, the pyrimidine ring is formed from the starting molecules glutamine, 
aspartate and 5-phosphoribosyl-1-pyrophosphate (PRPP). In the salvage pathway, the 
breakdown products of nucleic acids are recycled and/or nucleosides are imported from 
extracellular sources through membrane transporters (115, 116). The relative contribution of 
these two pathways depends on the active needs of the cell. Highly proliferating cells, like 
cancer cells or activated immune cells, are more dependent on the de novo pathway due to 
their greater need for nucleic acids and cellular components such as cell membrane precursors 
and second messengers (117, 118). Non-dividing or resting cells, on the contrary, have 
relatively lower demands and can satisfy their requirements by the less energy dependent 
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salvage pathway (117). The molecule that is central to both these pathways is uridine 
monophosphate (UMP), which is the precursor for all pyrimidine ribonucleotides. 
1.3.1.1 De novo pyrimidine ribonucleotide synthesis and DHODH 
In the de novo synthesis pathway, UMP is synthesized from glutamine, aspartate and PRPP 
by the catalytic activity of three different enzymes. First, the precursors are catalyzed in three 
steps by the multifunctional enzyme CAD (carbamoylphosphate synthetase II, aspartate 
transcarbamylase and dihydroorotase) to form dihydroorotate. Next, this is oxidized to orotate 
by the action of dihydroorotate dehydrogenase (DHODH), which is the only enzyme in the 
pathway located in the mitochondria. The last enzyme of the pathway, the bifunctional 
uridine monophosphate synthetase (UMPS), catalyzes the formation of UMP in two steps 
through the action of its orotate phosphoribosyltransferase and orotidine monophosphate 
decarboxylase activities (115, 116) (Fig 5). 
As mentioned above, DHODH catalyzes the fourth step in the de novo pyrimidine 
ribonucleotide synthesis pathway. In mammals, it is located in the inner mitochondrial 
membrane where it is known to catalyze the oxidation of dihydroorotate to orotate in the 
presence of the cofactor flavin mononucleotide (FMN) by the transfer of electrons to 
ubiquinone (CoQ) to form ubiquinol (CoQH2). Ubiquinol is used by complex III of the 
electron transport chain (117, 119). DHODH has two domains; a large catalytic domain 
(CAT) which contains the active site, and a small domain referred to as the quinone tunnel 
(QT) where ubiquinone binds (117). The QT is considered the most important site for 
enzyme inhibition, based on the binding characteristics of the enzyme’s two established 
inhibitors brequinar and teriflunomide (120, 121).   
Figure 5. De novo pyrimidine nucleotide synthesis pathway (129). Reproduced with 
permission from Elsevier all copyright retained (2019). 
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1.3.1.2 The salvage pathway of pyrimidine ribonucleotide synthesis 
The precursors to the salvage pathway can be obtained from endogenous sources, like the 
breakdown products of nucleic acids, as well from the extracellular environment. In this case, 
precursors must be imported through membrane transporters. The salvaged products can then 
be processed by the salvage pathway enzymes to synthesize UMP. These enzymes include 
uridine phosphorylase, that converts uracil to uridine, and uridine kinase, which converts 
uridine to UMP (115, 122). Another important enzyme, cytidine deaminase, is responsible for 
converting cytidine to uridine (123).  
The import of nucleosides requires the use of specific nucleoside transporters due to the 
hydrophilic property of these molecules. Nucleoside transporters can be divided into two 
classes: equilibrative and concentrative. The human equilibrative nucleoside transporters 
(ENT1-4, also known as SLC29A1-4) are bidirectional sodium independent transporters. 
ENT1 and 2 transport purine and pyrimidine nucleosides, whereas ENT2 and 3 additionally 
transport nucleobases (124, 125). ENT4, however, is only selective for adenosine and organic 
cations (126). Considering cellular localization, ENT1 and ENT2 can be found both on 
cytoplasmic and intracellular membranes, whereas ENT3 is primarily found on intracellular 
membranes and ENT4 on cytoplasmic membranes (see table 2 for tissue specific 
information).  
Table 2: The SLC28 and SLC29 transporter families (125). Reproduced with permission from Elsevier all 
copyright retained (2013). 
Human gene 
name and 
locus 
Protein name 
and UniProt 
accession 
Transport type/cation coupling 
stoichiometry 
Predominant tissue and subcellular 
distributions 
SLC28A1 
15q25.3 
CNT1 
O00337 
Concentrative 1:1 sodium:nucleoside Kidney, liver, small intestine. Primarily plasma 
membrane-located. 
SLC28A2 
15q15 
CNT2 (alias 
SPNT) 
O43868 
Concentrative 1:1 sodium:nucleoside Heart, skeletal muscle, liver, kidney, intestine, 
pancreas, placenta and brain. Primarily plasma 
membrane-located. 
SLC28A3 
9q22.2 
CNT3 
Q9HAS3 
Concentrative 2:1 sodium: nucleoside 
1:1 proton: nucleoside probably 1:1:1 
sodium:proton:nucleoside 
Widely expressed, most abundant in mammary 
gland, pancreas, bone marrow, trachea and 
intestine. Primarily in plasma membrane, but 
intracellular in some cell types and splice 
variants. 
SLC29A1 
6p21.1 
ENT1 
Q99808 
Facilitated diffusion Widely expressed, primarily in the plasma 
membrane but also in nuclear and mitochondrial 
membranes. 
SLC29A2 
11q13 
ENT2 
Q14542 
Facilitated diffusion Particularly abundant in skeletal muscle but 
widely expressed, primarily plasma membrane-
located but has also been detected in nuclear 
membranes. 
SLC29A3 
10q22.1 
ENT3 
Q9BZD2 
Unclear, possibly proton-linked. Widely expressed, intracellular (late 
endosomal/lysosomal and mitochondrial 
membranes). 
SLC29A4 
7p22.1 
ENT4 (alias 
PMAT) 
Q7RTT9 
Unclear, possibly proton-linked. Heart, brain, and skeletal muscle. Primarily 
plasma membrane-located. 
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The human concentrative nucleoside transporters (CNT1-3, also known as SLC28A1-3) are 
unidirectional sodium dependent active transporters. CNT1 preferentially transports 
pyrimidine nucleosides, CNT2 purine nucleosides and CNT3 both pyrimidine and purine 
nucleosides (124, 125). CNT1 and 2 are primarily located in the cytoplasmic membrane, but 
CNT3 can be found both on intracellular and cytoplasmic membranes (see table 2) (125). All 
the CNTs can transport uridine, and have a higher affinity for uridine than the ENTs (124, 
125) but a lower turnover rate of transport (125, 127).  
 
1.3.2 DHODH inhibitors with relevance to cancer 
The relevance of DHODH in cancer was first reported in 1960 when its high expression was 
seen in leukemia cells (128). Afterwards, several investigations that had encouraging results 
in preclinical studies led to the discovery of the potent DHODH inhibitor, brequinar (129).  
Initial studies in the 1980’s with brequinar on tumor xenograft models revealed promising 
anticancer effects on breast, colon, lung and stomach tumors (130). Later, the mechanism of 
action of brequinar was linked to its ability to inhibit DHODH (131). Further studies on 
cancer cell lines showed that continuous brequinar treatment was necessary to prevent cell 
proliferation, and that rapidly dividing cells were more sensitive relative to slower ones (130, 
132). With the success in preclinical results, brequinar was tested on patients. However, the 
drug demonstrated unsatisfactory responses in a number of different cancers, including breast 
(133), melanoma (134), colon (135), lung (136) and gastrointestinal (137). Therapeutic 
responses were not detected even at higher doses of the compound. To help understand the 
failure of these patients to respond to brequinar treatment, one needs to look at the drugging 
schedule and plasma uridine levels. Most patients in these trials were administered brequinar 
at high dose once every week. Furthermore, plasma uridine levels were reported to decrease 
by 40 to 80% after 6 hours to 4 days of drug administration. However, approximately a week 
after the treatment, plasma uridine levels were reported to spike to above 150%. As 
mentioned earlier, a continuous treatment with brequinar is necessary to show anti-
proliferative effects. It is likely that the dosing schedule of the trials did not lead to 
continuous suppression of DHODH and that plasma uridine levels weakened the response to 
the compound. In light of the poor results in the clinical trials, no further clinical testing was 
continued with brequinar (129). 
It was not until 2016 that brequinar once again resurfaced in the cancer field as a strong 
inducer of differentiation in acute myeloid leukemia cells (138). Since then, many potent 
DHODH inhibitors have been synthesized and are being tested as anticancer agents. Bayer 
has started clinical trials with a very potent DHODH inhibitor, BAY 2402234, for acute 
myeloid leukemia. Teriflunomide, the active metabolite of the prodrug leflunomide, is a 
DHODH inhibitor that is clinically approved for multiple sclerosis (139). Leflunomide is also 
clinically approved for rheumatoid and psoriatic arthritis (140). Despite being marketed as an 
anti-inflammatory drug, leflunomide also demonstrates anticancer activity in multiple cancer 
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cell lines such as multiple myeloma (141), neuroblastoma (142), non-small cell lung 
carcinoma (143) and medullary thyroid cancer (144). It is also undergoing clinical trials for 
multiple myeloma (NCT02509052). However, a point worth noting is that even though 
teriflunomide and leflunomide are well established DHODH inhibitors, they are not specific 
and have multiple targets, some of which include activation of aryl hydrocarbon receptor, 
inhibition of tyrosine kinases, as well as activation of PDGF and EGF (129, 144). Hence, the 
DHODH inhibitory activity of these drugs may not be the sole contributor for anticancer 
effects. Moreover, the half-life of teriflunomide is around 2 weeks, and it can still be detected 
in plasma for up to two years after end of treatment (145). 
 
1.3.3 Combination therapy with DHODH inhibitors  
Uridine is present in our plasma (varies between 3.1 to 4.8 µM in concentration) (146), and 
this may influence the response towards DHODH inhibitors. This is also highlighted in the 
past clinical trials where high uridine in the plasma most likely prevented an effective 
therapeutic response in patients treated with brequinar. It should be noted that even when the 
de novo synthesis of pyrimidine ribonucleotides is blocked, the salvage pathway is still 
available to compensate for decreasing concentrations of UMP. In such cases, combining a 
DHODH inhibitor with a nucleoside transport inhibitor may prove beneficial so that both 
pathways are blocked.  
There are many known nucleoside transport inhibitors (124, 147), and one of particular 
interest to this thesis is dipyridamole. Dipyridamole is a phosphodiesterase inhibitor that is 
normally used in the clinic as an anti-thrombotic drug (148); additionally, it is also a potent 
inhibitor of ENT1, as well as ENT2-4 with varying sensitivities (124). Furthermore, this drug 
has previously been investigated in different ocular disorders, using different routes of 
administration, such as intravitreal and oral, with no noted side effects (149). Interestingly, 
dipyridamole has been previously shown to reduce plasma uridine levels alone and in 
combination with PALA, an inhibitor of the aspartate transcarbamoylase activity of CAD, in 
cancer patients. However, the treatment did not prove to be as effective, possibly due to the 
inefficient inhibition of de novo pyrimidine synthesis by PALA (150, 151). Another potent 
ENT1 inhibitor is nilotinib, which is well-known as a Bcr-Abl tyrosine kinase inhibitor for 
treating chronic myeloid leukemia (147). CNTs can also be blocked to inhibit the salvage 
pathway. CNTS have a higher affinity to uridine but a slower turnover rate (ENT1: 200 
uridine molecules/s; CNT1: 10 uridine molecules/s) (124, 125). Thienopyrimidine 2′-
deoxynucleoside has been recently reported to be a potent CNT1 inhibitor (152). And among 
the tyrosine kinase inhibitors, imatinib has also shown inhibitory activity toward CNT2 (147). 
ENT and CNT expression can vary among different tumor tissues which have been reported 
to show higher or lower mRNA levels for the transporters relative to their normal 
counterparts. Higher mRNA levels for ENT1 have been reported in lung, breast, stomach and 
rectal cancers, whereas for ENT2 it was highly seen in breast, kidney, colon, stomach and 
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prostate cancers. CNT1 mRNA levels were high in ovarian cancers, and CNT2 in a majority 
of lung, prostate, breast, uterine and ovarian cancers (153). However, it should be noted that 
higher mRNA levels may not necessarily correlate to higher expression of these transporters.  
DHODH inhibitors may also be combined with drugs that can target downstream responses 
to DHODH inhibitors. As for example, the depletion of pyrimidine ribonucleotides is known 
to activate p53, and combination with an inhibitor of p53 degradation (e.g. MDM2 inhibitor) 
can potentiate the effect of the DHODH inhibitor (paper I). DHODH inhibitors can also 
sensitize cancer cells to chemotherapy and overcome resistance. In this regard, treatment of 
triple negative breast cancer with doxorubicin increases nucleotide synthesis to aid DNA 
repair. Pretreatment with leflunomide is able to deplete pyrimidine ribonucleotide synthesis 
and overcome doxorubicin resistance (154). Combination treatment of brequinar with 
cyclosporine was also reported to show synergistic effects in in vitro and in vivo models of 
melanoma (155). 
 
1.4 RETINAL NEURODEGENERATION 
Retinal neurodegeneration involves a group of heterogeneous disorders that progressively 
lead to vision impairment. The retina’s function may be compromised as a result of inherited 
mutations leading to protein dysfunction, such as retinitis pigmentosa (156); vascular defects 
in the retinal vasculature and choriocapillaris, including diabetic retinopathy and retinopathy 
of prematurity (46, 47); aging, e.g. age-related macular degeneration (44); and environmental 
insults, such as light-induced damage (157). Retinopathy has also been observed in patients 
treated with radiation (158) or chemotherapeutic drugs like cisplatin, etoposide and tamoxifen 
(159-161). Although the underlying mechanisms of these causes differ, the deconstruction 
and loss of photoreceptors, the remodeling and loss of inner retinal neurons as well as glia 
cell activation usually characterize the neurodegenerative events. The progressive neuronal 
cell death and limited synaptic connectivity in the retina lead to sensory deafferentation and 
loss of structural integrity (157, 162, 163).  
Retinal remodeling is a phenomenon that is evident in most retinal neurodegenerative 
disorders; especially those that involve photoreceptor degeneration. It occurs in three phases 
of structural and functional changes. The first phase involves photoreceptor stress and in 
some cases RPE cell stress (162-165). Usually, this begins with the rod photoreceptors 
followed by the cones if it is a rod-initiated degeneration or vice versa for a cone-initiated 
degeneration (163). Based on histological observations, the first sign of photoreceptor cell 
stress involves the mislocalization of opsins in the rod and cone photoreceptors from the OSs 
to other parts of the cell (162). The OSs of the photoreceptors also deconstruct and become 
shorter. The rods may start to develop neurites that either extend into the INL or retract 
further down into the ONL (163). Additionally, changes also start to occur in bipolar cell 
dendrite glutamate receptors. Phase two is accompanied by photoreceptor cell death and 
Müller cell gliosis where the Müller cells undergo hypertrophy and increased expression of 
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glial fibrillary acidic protein (GFAP). This results in the formation of the glial seal that 
isolates the retina from the RPE and choroidal blood supply (162-165). Microglia are 
activated and may cause further cell death (163, 165). At this phase, the bipolar cells also 
become completely deafferented by the loss of their glutamate receptors in the OPL and 
retraction of the dendrites into the INL. Sprouting of processes of bipolar, horizontal and 
amacrine cells may also occur in cone-sparing forms of retinal degenerations. Finally, in 
phase three the retina undergoes further remodeling as a result of bidirectional migration of 
surviving neurons along the vertical axis of the retinal tissue. This may involve the migration 
of surviving bipolar or amacrine cells to the GCL or the migration of ganglion cells to the 
INL, leading to complete disorganization of the retinal morphology. The processes of these 
neurons may also continue to sprout and form neurites that could tangle up and also cover 
great distances in the neural retina (162-165). In cases where some cone photoreceptors 
continue to survive, rod bipolar cells tend to rewire with the remaining cone pedicles. Such 
events lead to corruptive signaling circuits (162, 164, 165). 
 
1.5 MODELS OF RETINAL NEURODEGENERATION AND ADVANTAGES OF 
ORGANOTYPIC RETINAL EXPLANT CULTURE 
The biology and disease etiologies of the retina have been extensively studied on a number of 
different models in order to improve our knowledge of its functional mechanisms and for the 
development of therapeutic approaches. The models studied include in vivo, in vitro and 
organotypic culture systems. 
Mouse models have proven to be powerful tools in retinal research. Considering their 
similarity to the human genome and physiology, fast reproduction rates and low cost they are 
suitable for experimental research. However, what makes them ideal is that they can easily be 
modified by genetic interventions in order to recapitulate disease phenotypes. This has led to 
a wide variety of transgenic mice that carry mutations which alter developmental pathways or 
cellular mechanisms to help investigate relative human disorders and therapeutic strategies 
(166-168). Moreover, these mice also provide reproducible experimental systems since the 
genetic backgrounds can be controlled and the mutant and control mice only differ by the 
mutated gene being studied. This makes it possible to study the implications of a mutated 
gene in the same sex with same age littermates. Another advantage of using this model is 
their accelerated life span that can allow researchers to follow the progression of retinal 
disorders in a relatively short time period (166, 168).  
Although the mouse model has proved to be invaluable in retinal research, it is important to 
consider the fact that mouse retinas are not exactly the same as humans. The clearest 
distinguishing feature is the size of the eye which for mice has a diameter of ~ 4 mm and for 
humans ~25 mm (169). They are nocturnal animals and have a rod to cone ratio of 35:1 (167) 
whereas in humans it is 20:1 (170). The mouse retina is also dichromatic and does not have a 
macula (169). Pigs being diurnal animals have retinas similar in size and physiology to 
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humans, and, although they do not have a fovea, they have an area centralis consisting of a 
high density of cones (171, 172). Due to such features, the porcine model is also becoming 
quite popular in retinal research and transgenic pig models have also been generated (172). 
Although in vivo studies on animals are quite important for retinal research, another model 
that uses an in vitro culturing system for retinal tissue has received much attention. 
Organotypic retinal tissue culture systems provide an essential approach for direct 
experimental manipulation of therapeutic agents in a controlled environment (173). This 
model is superior to single cell culture systems in that it conserves the tissue morphology and 
most importantly the cell-to-cell contact and biochemical features for several days (174, 175). 
Intraocular injections into the eyes of mice may prove to be quite difficult since they are 
small and have a vitreous volume of ~7 µL leaving little space for drug intervention (176); 
however, in the in vitro organotypic cultures this restriction is eliminated. The disadvantage 
of this model is their short life spans in culture outside the in vivo environment; a number of 
modified culture systems are still under research to improve tissue survival (173, 174, 177). 
However, this feature of organotypic culture models is beneficial for investigating retinal 
degeneration and potential neuroprotective strategies (173). Since organotypic cultures share 
the benefits of in vivo and in vitro systems, they minimize the animals required for 
experimentation and help decrease ethical burden (174, 175).  
 
1.6 HUMAN NEURAL PROGENITOR CELL (HNPC) DERIVED 
NEUROTROPHIC SUPPORT AS A TREATMENT STRATEGY 
The regenerative capacity of the human retina is limited, so the loss of photoreceptors cannot 
be replaced. Currently there is no treatment for retinitis pigmentosa, which is a genetic 
disorder characterized by the loss of rods (178). Only supportive care is provided, as for 
example, by the use of nutritional supplements like vitamin A (179). The treatments for 
diabetic retinopathy target vascular defects and inflammation. However, the loss of 
photoreceptors is not accounted for (180, 181). The same holds true for other retinal 
neurodegenerative disorders. 
Gene therapy and stem cell therapy are under investigation to help prevent and replace 
photoreceptor loss. Although these therapies are very promising, there are still underlying 
problems. Gene therapy still comes with the challenges of gene delivery strategies, 
unpredictable dosage and different transfection rates in the retina and RPE (182). Moreover, 
gene therapy is mutation specific and may be difficult, although not impossible, to employ in 
retinitis pigmentosa (179). Stem cell therapy is aimed at replacing lost retinal cells by 
transplanting newly differentiated ones irrelevant of the disease mechanism. Successful 
transplantation of RPE cells have been reported, but photoreceptor cell transplantation may 
be challenging due to synaptic integration and the complex circuitry involved, although some 
preclinical studies have shown successful results (182-184). 
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Neuroprotective therapies aim to provide an environment to prolong retinal cell survival 
through altering their biochemical pathways independent of the underlying etiology of 
degeneration. A number of neurotrophic factors have been shown to have a neuroprotective 
effect on photoreceptor survival in retinal degeneration. Basic fibroblast growth factor 
(bFGF) was demonstrated to have an anti-apoptotic response in degenerating photoreceptors 
of the Royal College of Surgeons (RCS) rats that have inherited retinal dystrophy (185). In 
another study, it was shown that administration of ciliary neurotrophic factor protected 
photoreceptors in three different mutant mouse models; rd/rd (retinal degeneration), nr/nr 
(nervous) and Q344ter (truncated carboxyl terminus where last five amino acids of rhodopsin 
are removed); as well as in presence of light-induced damage (186). The beneficial effects of 
neurotrophic factors in combination, like VEGF and tissue inhibitor of matrix 
metalloproteinase-1 (TIMP-1), or brain derived nerve factor and ciliary neurotrophic factor 
was also reported and explained to interact synergistically for photoreceptor survival (187, 
188).  
The concept of using neurotrophic factors in combination can be further refined by the use of 
neural stem/progenitor cells. Neural progenitor cells are multipotent, have self-renewal 
capacity and can be conveniently expanded in culture (189). Unlike neural stem cells, they 
are more specific and this reduces their tumorigenic potential. Interestingly, human neural 
progenitor cells (hNPCs) have been used as a source of neurotrophic factors in retinal 
degeneration studies. Gamm and colleagues (2007) have shown hNPCs to survive for 
prolonged periods (up to 130 days post transplantation) and provide neurotrophic support to 
rescue photoreceptors in the RCS rat. The transplanted hNPCs were found to migrate and 
integrate into the retina forming a pigmented sub-retinal cell layer between the RPE and 
photoreceptors as well as distribute as individual cells in the inner retinal layers (190). In 
other studies, hNPCs used as feeder layers in mouse and rat retinal explant cultures were seen 
to provide neuroprotection solely by their ability to secrete a combination of diffusible factors 
through the culture medium (191, 192). 
Although hNPCs have their relevance in retinal neuroprotective therapy, they do not have the 
ability to regenerate photoreceptors once cell death has taken place. The use of hNPCs to 
treat retinal degenerative disorders may prove to be beneficial only when a significant 
number of photoreceptors still remain unaffected. If this window of opportunity is met, 
hNPCs can help prevent or slow the progression of further damage. Hence, it may be 
advantageous to combine hNPC neuroprotection with additional strategies like cell 
replacement therapy to help restore and maintain vision. 
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2 AIMS OF THE THESIS 
The overall aim of the thesis was to investigate ways to treat two different aspects of retinal 
dysfunction: (1) retinoblastoma, which is characterized by uncontrolled cell proliferation; and 
(2) retinal neurodegeneration, which is related to loss of retinal cells and functionality. 
Depletion of pyrimidine ribonucleotides through targeting the de novo and salvage pathways 
of synthesis was employed as a possible strategy to inhibit retinoblastoma cell growth and 
promote cell death; whereas, hNPCs were selected as a means to preserve retinal cells and 
their functionality in case of neurodegenerative events.   
The specific aims of the papers were: 
Paper I: To characterize a new class of molecules that activate p53, elucidate their 
mechanism of action and identify their target. Once the target was identified as DHODH, we 
wanted to further assess therapeutic implications. 
Paper II: To investigate if DHODH inhibitors as a single agent or in combination with 
nucleoside transport inhibitors can inhibit retinoblastoma cell growth and promote cell death. 
Paper III and IV: To characterize retinal neurodegenerative events in the in vivo pdgf-bret/ret 
retina and in vitro cultured porcine retinal explant with emphasis on photoreceptor 
degeneration, second order neuron remodeling and glia reactivity.  
Paper IV: To investigate whether treatment of porcine retinal explant cultures with hNPCs 
can preserve photoreceptors and minimize further neurodegenerative events. 
 
  41 
3 RESULTS AND DISCUSSION 
3.1 DISCOVERY OF A NOVEL DHODH INHIBITOR (PAPER I) 
3.1.1 Screening for novel p53 activating compounds 
In paper I, we set out to find novel small molecules that could activate p53 in tumors 
retaining wild-type TP53. To do this, we performed a phenotypic screen of 10,000 molecules 
from the DIVERSet and 10,000 additional molecules from the CombiSet libraries obtained 
from ChemBridge on two different p53 reporter cell lines. These p53 reporter cell lines had 
been previously obtained from T22 murine fibroblasts and the A375 melanoma cell line, by 
stably transfecting a pRGC-ΔFosLacZ construct expressing the bacterial lacZ-gene, encoding 
for β-galactosidase, under a p53-dependent promoter. After transfection, these cell lines were 
designated as the T22 pRGC-ΔFosLacZ and the ARN8 melanoma cell line respectively. 
Among these 20,000 molecules, 20 showed p53 transcriptional activity >1.5 fold in the 
ARN8 cells and <1.5 fold or no activation in the T22 cells. One of these molecules showed 
favorable medicinal chemistry characteristics which included the presence of a chiral center 
and absence of PAIN (pan-assay interference compound) (193) like features. This molecule, 
which was named HZ00 based on its tetrahydroindazole structure, was selected for further 
investigation. 
3.1.2 Characterization of HZ00 
To determine the mechanism of action of HZ00, we first did a large kinase panel assay with 
the compound to see if it had kinase inhibiting properties. The assay revealed no such activity 
for HZ00 and also confirmed a non-promiscuous targeting profile for the compound. To see 
if p53 activation was elicited as a result of DNA damage, the expression of proteins involved 
in the DNA damage pathway were investigated, which included phosphorylated (p)-ATM, p-
ATR, p-chk1 and p-serine-15 p53. Our results did not show any increase in expression for 
these proteins and also highlighted that HZ00 is not a genotoxic agent. The next reasonable 
option was that HZ00 may be an HDM2 inhibitor like the well-established molecule nutlin-3, 
which is known to stabilize p53 by blocking its degradation. Before engaging in this line of 
thought, we first went ahead to see the effect of HZ00 on the viability of ARN8 cells and 
normal HNDFs (human normal dermal fibroblasts) as well as determine its selectivity in 
comparison to nutlin-3 at similar concentrations. Compared to nutlin-3, HZ00 was more 
selective for ARN8 cells and portrayed a potentially better therapeutic window. Afterwards, 
we did cellular thermal shift assays (CETSA) with nutlin-3 and HZ00 to assess whether 
HZ00 is able to bind to HDM2 or HDMX. The CETSA assay shows the thermostability of a 
molecule upon binding to a ligand; the bound molecule is relatively more thermostable than 
the unbound molecule (194). Our results indicated that HZ00 was not able to bind to either 
protein whereas nutlin-3 was able to bind HDM2 but not HDMX. These results suggested 
that HZ00 was possibly able to stabilize p53 through some other mechanism. We performed a 
cycloheximide chase study (195) to see whether HZ00 was able to stabilize p53 and prevent 
its degradation by the protein synthesis inhibitor. However, there was no indication that the 
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main mechanism of action of the molecule was to stabilize p53. The remaining explanation 
was that HZ00 may increase p53 synthesis. To investigate this, we did a pulse-chase 
experiment using 35S labelled methionine and cysteine (196) to see the incorporation of these 
amino acids into newly synthesized protein in the presence of HZ00 or nutlin-3. The results 
showed that, indeed, HZ00 was able to promote the synthesis of p53 protein whereas nutlin-3 
did not have any significant effect at the studied time point. Further qRT-PCR experiments 
demonstrated no noticeable changes to p53 mRNA levels, which suggested that the p53 
synthesis induced by HZ00 may be related to increased translation rather than the increase in 
transcription of p53 mRNA.  
Since HZ00 was able to induce p53 synthesis and nutlin-3 can prevent p53 degradation, we 
thought that combining the drugs would illustrate a greater p53 effect in cancer cells by 
enhancing cell death. We did western blots to see p53 protein expression with both the agents 
as single treatments and in combination. And indeed, we saw that the drugs in combination 
showed much higher p53 expression compared to the single agents. To assess whether the 
combination would lead to increased tumor cell death, we did propidium iodide (PI) flow 
cytometry and analyzed the SubG1 percentage of cells. Compared to the single agents, the 
drug combination showed higher SubG1 percentage in ARN8 cell cultures. Additionally, 
SubG1 levels in the HNDFs were negligible in all cases. By this time, we had also tested that 
the R enantiomer of HZ00 was the active enantiomer responsible for activating p53’s 
transcriptional activity. Since the in vitro studies showed promising results, we performed 
xenograft tumor studies on NOD/SCID mice using R-HZ00 and nutlin-3. Compared to 
control, the increase in tumor volume was delayed by both the single agents and the 
combination, with the combination being more effective. Taking these results together, we 
continued our search for the drug target. 
3.1.3 R-HZ00 is a DHODH inhibitor 
To begin the process of target elucidation, we first did a time course analysis using BrdU/PI 
bidimensional flow cytometry with HZ00. The results showed that short treatment times 
caused ARN8 cells to accumulate in S phase and long treatments lead to increase in SubG1 
levels. Furthermore, HZ00 decreased cdc6 (cell division cycle 6) which plays an important 
role in licensing replication origins. A reduced expression of cdc6 may be associated to 
decreasing nucleotide levels (197). Based on these observations, we considered the possibility 
of a depletion of nucleotides to be related to the activity of HZ00. In support of this theory, 
we saw that HZ00 was also able to lower total RNA levels. So as a next step, we started to 
add nucleosides to see whether this would alter the response to HZ00 treatment. Among the 
nucleosides, only uridine was able to prevent R-HZ00 activity on ARN8 cell growth and p53 
transcriptional activity. This indicated that the drug was targeting pyrimidine ribonucleotide 
synthesis. To figure out which enzyme of the pathway was being targeted, we started to 
supplement ARN8 cells treated with R-HZ00 with the substrates and products of the enzymes 
in the de novo pyrimidine ribonucleotide synthesis pathway. From this, we concluded that the 
possible target for R-HZ00 was DHODH. In particular, we observed that supplementation 
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with the product of DHODH, orotate, rescued the cells from the treatment whereas 
supplementation with the DHODH substrate, dihydroorotate, had no effect. We confirmed 
this finding by treating the cells with two established DHODH inhibitors, brequinar and 
teriflunomide. Both these compounds were able to decrease ARN8 cell viability and increase 
p53 transcriptional activity, and both these effects were prevented by uridine 
supplementation. Thus, we could conclude ribonucleotide depletion, as a result of DHODH 
inhibition, was causing p53 activation. After these phenotypic studies, we tested R-HZ00 and 
S-HZ00 in an enzymatic assay with purified human DHODH enzyme.  In agreement with the 
cell-based studies, R-HZ00 was able to potently inhibit DHODH while the S enantiomer had 
negligible effects.  
3.1.4 HZ05 is a more potent HZ00 analogue    
Since the therapeutic effects of HZ00 on cells was observed at relatively high concentrations, 
we wanted to find a more potent molecule with similar medicinal properties and selectivity. 
After testing a number of analogues with the DHODH enzymatic assay, we found a molecule 
that fit our criteria and was able to inhibit DHODH at nanomolar concentration. This 
compound was named HZ05. HZ05 was able to inhibit ARN8 cell viability and increase p53 
transcriptional activity similar to HZ00, but at much lower concentrations. Furthermore, 
uridine supplementation was able to prevent these effects. Experiments in combination with 
nutlin-3a, the active enantiomer of nutlin-3, showed enhanced tumor cell killing both in vitro 
and in vivo. The similarity of its mechanism of action with HZ00 was also highlighted by an 
RNA sequencing experiment that was done with the two compounds. To investigate the 
binding mode of HZ05, we did crystallographic studies with racemic HZ05 and human 
DHODH. The crystal structure showed that the R enantiomer binds to the quinone tunnel of 
DHODH. This highlighted the specificity of the highly potent R-HZ05 compared to S-HZ05. 
During this time, we also decided to rescreen the 20,000 molecules that we started with as 
well as another set of 30,000 molecules that were previously screened in a paper published in 
2008 (198) to assess DHODH inhibition with the enzymatic assay. p53 transcriptional 
activity was also reassessed in the 30,000 molecules using the ARN8 cell line. Our findings 
showed that DHODH is a frequent target for a number of p53 activators. Moreover, we also 
discovered 12 different chemotypes that targeted DHODH. 
3.1.5 HZ compounds accumulate tumor cells in S phase with high p53 levels 
In our previous findings we observed that both HZ00 and HZ05 were able to accumulate 
ARN8 cells in S phase, and also enhance ARN8 cell death when combined with nutlin-3 or 
nutlin-3a. Next, we tried to see the effect of HZ00 and HZ05 in other cancer cell lines to 
ensure the effect is just not restricted to the ARN8s. Like the ARN8s, other cancer cell lines 
tested (SigM5, MV411 and U2OS) also responded with an initial accumulation of cells in S 
phase followed by increases in SubG1 levels. However, in the U2OS cell line, cells 
demonstrated a propensity to be in S phase. Further investigation showed that the cells at S 
phase had high levels of p53. This observation led us to think whether adding a p53 
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degradation inhibitor, when cells accumulate at S phase with high p53 levels, would enhance 
tumor cell death. To investigate this, we either co-treated U2OS cells with HZ05 and nutlin-
3a, or we pretreated cells for 72 h with HZ05 and followed the treatment with the addition of 
nutlin-3a. Interestingly, co-treatment of the drugs resulted in an arrested phenotype, whereas 
the pretreatment condition with HZ05 followed by nutlin-3a lead to cancer cell killing. These 
observations indicated that DHODH inhibitors could sensitize cancer cells to p53 degradation 
inhibitors by accumulating them in S phase with high p53 levels. 
 
3.2 A DHODH INHIBITOR IN COMBINATION WITH A NUCLEOSIDE 
TRANSPORT INHIBITOR PROMOTES RETINOBLASTOMA CELL DEATH 
(PAPER II) 
In paper I, we showed that DHODH inhibitors can activate p53 and lead to S phase 
accumulation followed by cancer cell death. Considering the molecular pathology of 
retinoblastoma, we thought that targeting DHODH may be a viable option. As previously 
mentioned in this thesis, retinoblastoma is typically a TP53 wild type tumor, and inactivation 
of RB1 leads to the loss of the cell cycle’s major G1-S checkpoint Rb, which is known to 
protect cells from unscheduled S phase entry. Since DHODH inhibitors lead to cancer cell 
death by accumulating cells in S phase, the use of these agents seemed rational in a 
retinoblastoma setting.  
3.2.1 DHODH inhibition affects retinoblastoma cell growth 
At the beginning of this project, we tried to assess the effect of brequinar on retinoblastoma 
cell growth using a WST-1 metabolic assay for cell viability and PI cell cycle flow 
cytometry. We treated two commonly used cell lines in retinoblastoma research, the Weri-
Rb1 and Y79, with brequinar at increasing concentrations (max 10 µM) for a period of 3 
days. The metabolic activity of both cell lines were seen to decrease with increasing 
concentration until reaching a plateau after approximately 1 µM of brequinar. However, the 
cell cycle was unaffected by the treatment. These results were unexpected because we were 
anticipating a possible increase in S or SubG1 phase of the cell cycle based on our findings in 
paper I. Since the retinoblastoma cell lines proliferate slowly, we decided to prolong the 
treatment to 6 days. Indeed, this treatment time was seen to cause cells to accumulate in S 
phase at lower concentrations, whereas at higher concentrations there was a mixture of S 
phase and SubG1 cells. A point to be noted is that the WST-1 assay measures cell metabolic 
activity as a readout for viability and proliferation, and assessing a drug that targets the 
mitochondria may not give an accurate readout for proliferation. This is because a reduction 
in respiratory activity by the drug may not necessarily reflect a reduction in cell number 
(199).  To account for this, in paper I an SRB (Sulforhodamine B) assay (200) was selected to 
determine cell growth and viability. This was not used in this project because the SRB assay 
is most suited for adherent cells. Therefore, we have to bear in mind that the readout from the 
WST-1 assay in these initial experiments, may actually reflect the metabolic activity of the 
cells and not the proliferation. 
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3.2.2 Combination of DHODH inhibitor with nucleoside transport inhibitor 
shows synergistic cancer cell killing effect 
Combinations between therapeutics are becoming more frequently considered as a strategy in 
cancer because they enhance cancer cell death and, therefore, reduce the chance of 
metastasis. This may be highly applicable in retinoblastoma because of its invasive nature. 
Importantly, combination of therapeutics also diminish the risk of drug resistance, as well as  
enable the use of lower drug concentrations to obtain better therapeutic windows (68). To 
enhance the therapeutic effect of brequinar, we considered whether simultaneous blocking of 
the salvage synthesis pathway of pyrimidine ribonucleotides would give a synergistic effect. 
We selected a human ENT1 inhibitor, dipyridamole, based on its current use in the clinic, and 
also because it was previously investigated to mitigate several ocular disorders (149). 
Dipyridamole as a single agent did not show any decrease in retinoblastoma cell metabolic 
activity and did not affect cell cycle profiles. This may indicate that retinoblastoma cells are 
more dependent on the de novo pyrimidine ribonucleotide synthesis pathway than on the 
salvage pathway. Interestingly, the combination of brequinar and dipyridamole led to 
synergistic effects in retinoblastoma cell killing. Time course studies with the drug 
combination showed an accumulation of S phase cells by 24 hours of treatment with an 
increase in SubG1 cells over time. By six days of treatment, both cell lines showed 
considerable increases in cell death which nearly reached 100%, based on single cell 
population gating. Flow cytometry experiments with a live/dead marker, which is similar to a 
dye exclusion assay, also confirmed these results. Brequinar as a single agent at the 
concentration tested was also able to significantly cause cell death in the Weri-Rb1 cells 
when treated for 6 days. Since it is known that the presence of uridine can affect the activity 
of DHODH inhibitors, we supplemented 5 µM of uridine to the cell cultures when drugging. 
The concentration of uridine selected was based on reference values for human plasma 
uridine concentrations (146), as it was difficult to find literature on uridine levels in the 
human vitreous humor. The drug combination was still significantly effective (p < 0.0001) at 
causing retinoblastoma cell death, even in the presence of 5 µM uridine, however, brequinar 
as a single agent lost its ability to induce cell death. 
To ensure that the combination therapy did not cause cell death in normal cells, we treated the 
retinal pigment epithelium ARPE-19 cells with the combination and did not see excessive 
cell death, however the proliferation of the ARPE-19 cells were slightly reduced. When 
considering retinal development, usually there is a sharp decline in retinal pigment epithelium 
cell proliferation after birth (201-203), which could mean that our current treatment strategy 
may not affect the retinal pigment epithelium. Retinal neuronal cells are usually postmitotic 
and are difficult to grow in culture unless they are immortalized. Hence, the effect of the 
treatment could not be assessed for normal retinal neurons. However, teriflunomide and 
leflunomide which are used in the clinic for multiple sclerosis and rheumatoid arthritis, 
respectively, as well as brequinar, have not been reported to cause adverse visual impairment 
to the best of our knowledge. On the other hand, as mentioned earlier in this thesis, current 
chemotherapeutic drugs can cause retinal damage as well as have other severe toxicities when 
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given systemically (158-160). The possible side effects of the combination of brequinar and 
dipyridamole on the retina, that might still be functional in retinoblastoma patients, need to be 
addressed through in vivo animal studies, in vitro organotypic studies or with retinal organoid 
systems. 
3.2.3 Activation of caspase 3 and 7 precedes cell death 
To try to determine the mechanism of cell death we did live cell imaging with a caspase 3/7 
substrate and YOYO-3. The caspase 3/7 substrate is cleaved by activated caspases 3 and 7, 
after which it is capable of binding to DNA and emit a fluorescent signal, while YOYO-3 is a 
cell impermeable nuclear dye. Our results showed that the combination treatment activated 
caspase 3/7 prior to YOYO-3 death signals, indicating an apoptosis mediated cell death. The 
same also held true for brequinar as a single agent. To clarify further, we assessed the protein 
expression of cleaved poly (ADP-ribose) polymerase-1 (PARP-1) in the Weri-Rb1 cell line. 
The proteolytic cleavage of PARP-1 by activated caspases 3 and 7 is considered a 
characteristic event of apoptosis (204). The expression of cleaved PARP-1 was also increased 
in the combination after 48 h of treatment, which was in agreement with the previous findings 
where caspase 3/7 signal was seen to increase after 1.5 days. However, although these 
experiments are indicative of apoptosis, further experiments with the pan caspase inhibitor Z-
VAD-FMK and the expression of other apoptosis markers (e.g. Bcl-2, Bax) need to be 
performed. Live cell imaging with the ARPE-19 cells using YOYO-3 did not show any death 
signal for the entire time span investigated. 
3.2.4 DHODH and nucleoside transport inhibition promotes retinoblastoma 
cell death irrespective of p53 status 
In paper I, we saw that DHODH inhibitors can activate p53. We wanted to see if the same 
was true in case of the retinoblastoma cells. We observed that p53 protein expression started 
to increase for the combination treatment after 48 hours. This reflected the fact that p53 
activation may not have led to caspase activation, which was observed to start before 48 
hours.  
Another interesting finding was that both brequinar as a single agent and in combination with 
dipyridamole showed effect in a p53 mutant retinoblastoma cell line, which initially started 
with an S phase accumulation of cells, followed by increase in SubG1 levels. This p53 
mutant cell line was derived from a metastatic site. Although p53 mutations in retinoblastoma 
are quite rare, metastatic tumors may tend to harbor p53 mutations (205). This highlighted the 
possibility for this treatment strategy to target both p53 wild-type and p53 mutant 
retinoblastoma cell backgrounds.  
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3.3 CHARACTERIZATION OF NEURODEGENERATIVE EVENTS IN AN IN 
VIVO AND IN VITRO MODEL OF RETINAL DEGENERATION 
3.3.1 Pathways to photoreceptor degeneration (paper III and IV) 
Photoreceptors are sensory neurons that have the ability to survive during the entire lifespan 
of an organism. However, they are susceptible to injury or death as a result of 
neurodegenerative pathologies. Since these neurons are postmitotic, their loss may have a 
profound impact on vision quality. If the underlying disease mechanisms are not properly 
addressed, the loss of the photoreceptors can eventually lead to blindness. In these papers, 
photoreceptor degeneration was assessed by studying cell death, cone outer segment 
shortening or loss, opsin mislocalization, and synaptic disassembly in the OPL. 
3.3.1.1  Loss of the pdgf-b retention motif leads to photoreceptor cell death and cone 
outer segment shortening (paper III) 
In case of the pdgf-bret/ret mutant mouse retinas, vascular defects in the choriocapillaris and 
the intraretinal vessels were evident from postnatal day (P)10. In the older mutants, the 
defects became increasingly severe with total disorganization of the vascular bed including 
distorted and frequently hyperfused vessels. Aberrant NG2 profiles were also apparent, 
reflecting improper pericyte investment to the vessels. The abnormal tortuous phenotype of 
the vessels could be related to endothelial cell hyperproliferation due to defective pericyte 
recruitment which is known to negatively regulate endothelial cell proliferation (206, 207). 
Interestingly, cone outer segment shortening was observed to start from P10 and continued to 
shorten in the older mutants. Based on TUNEL assay and cc-3 immunostaining, there was a 
dramatic increase in photoreceptor death between P10 to P15. These observations could be 
explained by the insufficiency of the choroidal blood supply in the mutant mice to meet the 
high metabolic requirements of the photoreceptors, which increases when the mice open their 
eyes at around P14. The deficiency in proper nutrient and oxygen balance may start with 
shortening of outer segments and eventually lead to cell death when the actively functioning 
cones create an increasing burden on the already compromised vascular network. Another 
crucial factor leading to photoreceptor death and cone OS shortening could be retinal 
detachment from the RPE which was also observed at P15 and P28. Interestingly, the rod 
photoreceptors seemed to be more vulnerable to cell death compared to the cones. This was 
assessed by TUNEL and rhodopsin colabeled rod cells which were usually present towards 
the inner aspect of the ONL, and also by the fact that the cone photoreceptor density, 
quantified by the number of OSs/mm, was only significantly reduced at P28. Rod 
degeneration followed by cone degeneration has been shown in other models of retinal 
degeneration as well (164, 208, 209). Another interesting observation was the higher 
proportion of single TUNEL+ photoreceptor cells compared to cc-3+ cells. TUNEL labels 
fragmented DNA, which is known to occur in apoptotic and necrotic cells. Since a high 
number of cells were only TUNEL+ without cc-3 co-labeling, it could be that alternative 
death mechanisms are involved apart from apoptosis. In other studies, it has been 
demonstrated that photoreceptor death can also be linked to autophagy, necrosis and caspase-
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independent calpain mediated pathways (210-212). However, another scenario may be that 
after cc-3 activates the endonuclease caspase activated DNAse to induce DNA fragmentation 
it is no longer detectable in the cell due to its rapid activity and transient nature. 
3.3.1.2 Retinal explant culture leads to photoreceptor cell death, cone outer segment loss 
and opsin mislocalization (paper IV) 
In the retinal explant cultures, photoreceptor cell death was assessed by TUNEL assay after 1, 
2 and 3 days of culture. As expected, cell death increased with days in vitro (div) and a 
significant difference was seen at the third day of culture relative to uncultured controls. This 
fast rate of photoreceptor loss is thought to be related to the explantation procedure, which 
involves isolation of the retina from the systemic blood circulation and detachment from the 
RPE. The RPE and photoreceptor OSs together form a functional unit that allows for the 
proper health and maintenance of the photoreceptors (213). In fact, in previous studies with 
retinal explant cultures that included the RPE, there was a slower rate of photoreceptor 
degeneration compared to those that excluded the RPE (173, 214). When assessing cone OS 
shortening and conservation, it was observed that both cultured and hNPC cocultured 
explants underwent OS shortening; however, the only cultured explants had a significant 
reduction in OS conservation. The cone OS is known to contain opsin, which is the primary 
visual pigment in the cone phototransduction pathway.  After opsin is synthesized in the 
endoplasmic reticulum it is transported to the OS. In a normal retina, opsin remains restricted 
to the OS unit, however, it has been reported that in neurodegenerative pathologies there may 
be opsin mislocalization to other parts of the cone cell, which may contribute to 
photoreceptor apoptosis (212, 215, 216). In this study it was demonstrated that after 3 div, the 
cultured explants had opsin mislocalized to the cell somata, axon and synaptic pedicle. 
Quantifying opsin labeled cone pedicles revealed a significantly higher number of cone 
photoreceptors to have mislocalized opsin than hNPC cocultures. The normal retinas had 
opsin restricted to the OS. Since the presence of the OS is crucial for the proper shuttling of 
the pigment, its loss may lead to the undesired accumulation of opsin in other components of 
the cell and increase cell burden. Consequentially, this may lead to an ER stress response 
causing cell apoptosis (212, 215-217). Interestingly, similar to paper III most of the TUNEL+ 
photoreceptors seemed to be labeled by the rod population, reflecting the vulnerability of 
these cells to the culture paradigm. Although rhodopsin, the visual pigment found in rods, 
was not investigated in this study it could be that rhodopsin accumulation may be a 
contributing factor to rod photoreceptor death. Studies on rat retinal explants with detachment 
from the RPE have previously connected rod photoreceptor death to rhodopsin accumulation 
(192). 
3.3.1.3 Synaptic disassembly (paper III and IV) 
The photoreceptor axon terminals are highly sophisticated functional structures that form 
synapses with the second order neurons in the OPL. Synaptic disassembly may lead to 
impaired transmission of phototransduction signals from the ONL to the INL and eventually 
compromised vision. Immunolabeling for synaptic proteins ribeye (paper III) and PSD-95 
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(paper IV) together with PNA staining for cone pedicles (paper III and IV) was used to assess 
synaptic integrity of the photoreceptor axon terminals. Ribeye is a major protein component 
of the unique photoreceptor ribbon synapses that allow for high rate neurotransmission. The 
ribbon, present at the active zone of the synaptic terminal, provides a reservoir of synaptic 
vesicles that are immediately available for exocytosis (11). In the immunofluorescence 
studies of paper III, ribeye immunostaining appeared as a uniform band of punctae in the 
OPL with a characteristic horseshoe shape in the P15 and P28 control mice. However, in the 
pdgf-bret/ret P15 and P28 mutants the expression of ribeye was reduced and disorganized, 
especially in rosette dominant regions, and had altered morphology. In the P28 mutants, 
ribeye immunostaining was found to be scattered in the ONL. The reduction in ribeye 
expression could be due to disrupted transport of ribeye to the photoreceptor terminals or due 
to the loss of the photoreceptors. And the presence of the proteins in the ONL may be 
explained by photoreceptor axon retraction, which could be related to the rod population 
because PNA labeled cone pedicles mostly remained restricted to the OPL. The loss of the 
characteristic horseshoe shape may be because of the degradation of the ribbon complex. It 
has been reported that the stability of the ribbon complex can be modified by Ca++ 
homeostasis (218). In a mouse model of glaucoma, investigation of the ribbon synapses also 
showed altered ribeye protein shape and decreased expression, which were thought to be 
related to disrupted Ca++ homeostasis (219). In another study it was found that loss of the 
calcium binding protein, CaBP4, caused an imbalance in Ca++ homeostasis which eventually 
affected photoreceptor ribbon synapse integrity (220). In case of the cone pedicles, the older 
mutants had tendencies of losing their PNA staining possibly due to cone cell death. 
However, as mentioned earlier, the pedicles retained their position in the OPL. 
In paper IV, synaptic integrity was investigated by PSD-95 expression in the photoreceptor 
synaptic terminals. PSD-95 is a scaffolding protein that aids neuronal signaling by means of 
interacting with different glutamatergic receptors, cell adhesion molecules, and cytoskeletal 
elements (221, 222). In normal retinas, PSD-95 appeared as a uniform and distinct band in 
the OPL. However, in the cultured and cocultured explants frequent gaps devoid of PSD-95 
immunostaining was observed possibly due to the rapidly degenerating rod population. In a 
previously reported study on a transgenic porcine model of retinitis pigmentosa, it was shown 
that PSD-95 immunoreactivity was lost from rod axon terminals but persisted in cone 
pedicles as a result of early rod degeneration (223). In this study, photoreceptor terminals in 
both the experimental groups depicted three different features: (a) intact synaptic terminals 
with low intensity PSD-95 labeling (b) condensed terminals with high intensity PSD-95 
labeling and (c) PSD-95 labeled terminals with high or low intensity L/M-opsin colabeling. 
In case of intact terminals, PSD-95 was seen to distinctly outline the plasma membrane of the 
cone pedicles and rod spherules at low intensity. Condensed synaptic terminals showed high 
intensity PSD-95 labeling and were considered to represent impaired synaptic integrity. The 
cultured explants were seen to have a significantly higher number of condensed PSD-95 
labeled terminals compared to the hNPC cocultured explants. Moreover, these condensed 
PSD-95 labeled terminals would frequently colabel with high intensity L/M-opsin labeled 
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condensed cone terminals. Interestingly, in the same study by Blackmon and colleagues (223) 
it was also reported that PSD-95 labeled pedicles appeared condensed and small in the 
transgenic porcine model. The loss of the cone pedicle’s triangular shape has also been 
observed in human retina explant cultures (224). Additionally, there was also a significant 
reduction in the number of PNA labeled cone pedicles in the cultured explants compared to 
the cocultures. Similar to paper III, the pedicles were restricted to the OPL. 
In both paper III and IV, it was difficult to confirm whether the loss of synaptic integrity 
occurred before or after photoreceptor degeneration because of the selected time points. In 
many studies it has been observed that synaptic integrity is compromised upon extensive 
photoreceptor loss (225-227). Due to the rapid death of photoreceptors in such short time 
frames; i.e. between P10 to P15 in the pdgf-bret/ret mutant retinas and within only 3 days of 
culture for the retinal explants; it could be considered that photoreceptor cell death may be an 
upstream event for synapse disassembly. 
3.3.2 Second order neuron responses to retinal neurodegeneration (paper III 
and IV) 
It has been previously reported that a causative factor for second order neuron defects may be 
related to loss of synaptic connectivity with the photoreceptor terminals as a result of 
compromised photoreceptor terminal integrity (224, 228, 229). We hypothesized that 
extensive photoreceptor degeneration together with OPL disruptions would also translate to 
second order neuron impairment. Moreover, since the intra-retinal vasculature provide the 
necessary support to maintain the health and survival of the second order neurons, 
abnormalities of the vasculature in the pdgf-bret/ret mutants as well as vascular regression and 
loss of vascular perfusion in the cultured explants could be additional contributing factors. As 
expected, and discussed below, rod bipolar cells and horizontal cells underwent remodeling 
in response to retinal degeneration.  
3.3.2.1 Rod bipolar cell responses (paper III) 
In paper III, rod bipolar cells were detected by PKC-α immunostaining. Compared to the 
controls, the pdgf-bret/ret mutant P15 retinas rod bipolar cell defects were characterized by a 
reduction in their dendritic tufts, close proximity of the cell bodies to the ONL and the 
disorganized arrangement of the cells in the INL especially in rosette dominant regions. In 
case of the P28 mutants, an additional feature was the sprouting of rod bipolar cell dendrites 
to from single neurites that extended into the ONL. Bipolar cell sprouting and dendrite 
atrophy were also reported in the CaBP4 knockout mouse model (220), which highlights the 
fact that photoreceptor synaptic terminal defects may indeed be a consequential factor to 
bipolar cell remodeling in this study. An explanation for bipolar cell neurite sprouting to the 
ONL may be due to the retracting rod terminals, which is known to generate a tractional force 
that induces a growth response from postsynaptic neurons (228).  
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3.3.2.2 Horizontal cell responses (paper IV) 
In paper IV, horizontal cell remodeling in the cultured retinal explants was detected by 
calbindin immunoreactivity. This included cellular defects related to dendrite atrophy, 
reduction in cell somata, mislocalization of the cells to the ONL and in rare occasions the 
formation of neurites extending to the ONL. In a study conducted on human retinal explant 
cultures (224), it was found that synaptic connections were lost in condensed presynaptic 
terminals due to alterations in synaptic invaginations required for horizontal dendrite 
contacts. This in turn led to dendrite atrophy. Other insults leading to neurite outgrowth may 
be related to defective calcium ion release machinery in photoreceptor synapses (230). It is 
possible that condensed PSD-95 immunoreactive synapses harbor defective PSD-95 proteins; 
since PSD-95 is known to regulate Ca++ pump localization in photoreceptor synapses (231) it 
is likely that these synapses may have defective synaptic activity which in turn leads to 
neurite formation from the second order neurons. These results indicate that the horizontal 
cell changes may be associated to photoreceptor degeneration and synaptic disassembly. 
Although morphological changes in horizontal cells were clearly defined, western blot and 
qRT-PCR results were somewhat inconsistent with the immunohistochemical findings. This 
may be due to the fact that calbindin also labels amacrine cells of the inner retina and it is 
likely that these may also have a contribution to the protein and gene expression profiles. It 
seems that in this case the immunohistochemical results provide a means of distinguishing 
multiple cells expressing calbindin. A similar discrepancy in visual and western blot results 
was also experienced by Nagar and colleagues in their studies on an inducible mouse model 
for retinal degeneration (229). 
3.3.3 Glia responses (paper III and IV) 
In response to retinal degenerative events, the glial cells are known to shift to a reactive 
gliosis phase where they show altered morphology and biochemistry. The hallmark features 
include increased expression of GFAP for the Müller cells and a change in morphological 
phenotype for the microglia. These characteristic events have been previously reported in 
pathologies related to macular degeneration (232), diabetic retinopathy (233) and retinal 
detachment (228). Although the reactivity of Müller cells may prove to be beneficial initially, 
continued gliosis may tend to be quite the contrary. Similarly, a continued microglial 
response may prove detrimental to the retinal tissue although it may serve to have a 
neuroprotective function initially. We observed gliotic responses in both the in vivo and in 
vitro models of retinal degeneration which are discussed below. 
3.3.3.1 Müller cell gliosis (paper III and IV) 
In paper III, Müller cell gliosis in the form of increased GFAP expression throughout the cell 
was seen in the P15 and P28 mutants. Usually in the P15 mutants, the gliotic response was 
more prominent in the rosette dominant regions. However, at P28 the Müller cells portrayed 
intense GFAP labeling and seemed to be hypertrophic. The P7 and P10 mutants, like all the 
control retinas, only showed GFAP labeled astrocytes near the vitreal aspect of the retina and 
the optic nerve. Müller cells are sensitive to vascular injury, (233) and interestingly the gliotic 
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response was seen at a time point between P10 and P15 during which time the hyaloids 
vessels are replaced by mature vessels (45). Since the mutants harbor a defect in the pdgf-b 
retention motif there is neovascularization failure and the vessels that form malfunction. Such 
an event is likely to trigger a gliotic response. During this response, cytokines are secreted 
that are neuroprotective but later are involved in severe gliosis (234-236) and possibly 
photoreceptor death. However, based on the time points studied it was difficult to say 
whether the gliotic response appeared before or after photoreceptor degeneration; the P13 
time point may have been interesting for these investigations. Nonetheless, Müller cell gliosis 
intensified with photoreceptor death especially in rosette dominant regions of the P15 and 
P28 mutants. It could be that tractional pull from the gliotic Müller cells together with the 
distorted vasculature caused retinal detachment, which in turn induced photoreceptor death. 
In paper IV, Müller cell gliosis is thought to increase as a result of retinal detachment from 
the RPE in the explants. Müller cell gliosis is a common feature of explants consisting of 
adult retinal tissue (237). In normal control porcine eyes, GFAP labeled thin strands of 
Müller cells were seen to span the retina from the inner to outer limiting membrane and is 
thought to be a common feature of porcine retinas (191, 237). In the 3 div cultures, the Müller 
cells were heavily gliotic and hypertrophic with GFAP labeling in their processes and cell 
bodies. Photoreceptor degeneration was also significantly high in the 3 div explants as 
assessed by cell death and synapse pathology which may have been factors either 
contributing to or influenced by the gliotic response; since GFAP immunolabeling was not 
investigated at earlier time points, it was difficult to determine.  However, the 
immunohistochemistry results were not paralleled by the western blot findings, which 
indicated similar levels of GFAP expression in the normal and cultured explants. This may be 
because the 3 div cultures underwent a loss of neurons that resulted in thinner nuclear layers 
which reduced the entire height of the neuro retina. The Müller cells in the normal retinas, 
although not gliotic, may express the same level of GFAP as the gliotic 3 div cultures because 
the cells are longer, whereas in the 3 div cultures the cells are shorter but then again have 
thicker trunks due to hypertrophy. Another possibility may be due to different subsets of cells 
expressing GFAP, like the astrocytes. However, the qRT-PCR results did agree with the 
immunohistochemistry findings. A reasonable explanation for the discrepancy in results may 
be related to the animal set used for the different experiments. Immunohistochemical and 
qRT-PCR analysis were done on the same animal group whereas western blot data were 
generated on a different set of animals. This may reflect the importance of the set of animals 
used for such analysis, and also the presence of possible inter/intra species variation. 
3.3.3.2 Microglia responses (paper III) 
In the pdgf-bret/ret mutant retinas, the majority of the microglia were found in their ramified 
state residing in the inner layers at P7 and P10, which were similar to the control retinas at all 
time points. In the P15 and P28 mutants a high population of the microglia were observed to 
morph into their reactive amoeboid like phenotype. The Iba1 or TSPO labeled reactive 
microglia were quantified at P10 and P15 and were found to be significantly higher in the 
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P15 mutants relative to control retinas; a time point characteristic of vascular defects, 
photoreceptor degeneration, retinal detachment and rod bipolar cell remodeling. In some 
cases, single reactive microglial cells were found in the ONL. As mentioned before, initially 
microglia reactivity is associated to neuronal protection, however a sustained reactive 
response contributes to further neuronal damage. Microglia reactivity is thought to be related 
to cytokine feedback mechanisms and a dysregulation of microglial cytokine production is 
associated to neurotoxicity (235, 238). There have been reports where cytokine release from 
reactive microglia and Müller cells has been correlated with the promotion of photoreceptor 
survival or induction of their apoptosis in retinal pathologies (156, 234, 238). In a study on 
retinoschisin-deficient mice it was found that microglia reactivity could trigger events that 
lead to photoreceptor apoptosis (239). Based on the time points selected and the results 
obtained from this study it is difficult to determine whether microglial reactivity precedes 
photoreceptor cell death. However, in the older mutants it can be speculated that continued 
microglial reactivity may be involved in further photoreceptor damage and loss. 
 
3.4 HUMAN NEURAL PROGENITOR CELLS PROVIDE NEUROPROTECTION 
TO CULTURED RETINAL EXPLANTS (PAPER IV) 
In paper IV, it was investigated whether hNPCs in coculture with porcine retinal explants 
could provide neuroprotection and prevent photoreceptor degeneration, second order neuron 
remodeling and Müller cell gliosis. Previous studies have reported that hNPCs secrete a 
combination of neurotrophic factors that may have a synergistic effect on the preservation of 
neurons in retinal pathologies (187, 190, 191). In this study, conditioned medium from hNPC 
cultures was found to consist of significant amounts of EGF, eotaxin, FGF-2, IL-2, IL-4, IL-
6, IL-8, MCP-1, TGF-α and VEGF. A variety of different neurotrophic/growth factors are 
known to support photoreceptors in retinal degenerations. Initial studies on cultured rd1 
mouse retinas showed that growth factors in combination produced synergistic effects that 
could significantly rescue photoreceptors (188). As hNPCs have the potential to secrete a 
multitude of these factors simultaneously, the cells have been reported to be subretinally 
injected (190) or used as feeder layers in explant cultures (191) to demonstrate their 
neuroprotective ability. Amongst these factors, FGF-2 and VEGF have been linked to 
photoreceptor survival (187, 190, 191, 240). EGF and TGF-α, both ligands of EGF-receptor, 
are known to regulate neuron development, survival and function; EGF has been shown to 
counteract toxic insults like excitotoxicity, oxidative stress, and ischemia (241-248). Amongst 
the immunomodulatory cytokines, the anti-inflammatory cytokine IL-4 has been found to 
inhibit microglia reactivity and also decrease their secretion of neurotoxic molecules. 
Moreover, IL-4 was found to enhance the survival of axotomized retinal ganglion cells either 
in culture or in vivo (249-251). MCP-1, IL-2, and IL-6 are known to have variable impacts on 
the central nervous system and their responses highly depend on the environmental milieu 
and simultaneous presence of other factors (251-255). For instance, in a study it was shown 
that MCP-1 had both neurodegenerative and regenerative roles after neurotoxin injection into 
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the intrahippocamal region of the brain. Shortly after injection, neuronal apoptosis was 
related to elevated MCP-1 levels, which later decreased when significant apoptosis had taken 
place. However, 3 weeks post-injection MCP-1 levels were observed to rise again during a 
phase of significant neuronal regeneration (252). In another study it was found that at specific 
concentrations, MCP-1 proved to be a neuroprotectant for retinal ganglion cell survival in 
experimental glaucoma (254). Additionally, it was found that transgenic mice lacking MCP-1 
or its receptor showed age-related macular degeneration like characteristics (256). Both IL-2 
and IL-6 have been implicated in neurodegenerative mechanisms; however, studies have also 
highlighted these cytokines’ neuroprotective attributes in the central nervous system by 
supporting the survival and physiological functioning of various neurons (251). In fact, IL-2 
and IL-6 have been shown to enhance the survival of axotomized retinal ganglion cells in 
culture (249, 257). Whereas, IL-6 has also been shown to preserve photoreceptors in an 
experimental model of retinal detachment (258). 
It must be mentioned that the cytokines discussed here is only limited to the milliplex assay 
used to detect these factors. There may of course be various other cytokines at play to 
preserve the neurons from the degenerative cascade observed in the explant cultures. 
Moreover, it cannot be dismissed that the explants themselves also intrinsically produce 
factors in response to both the degenerative culture paradigm and the presence of hNPC-
derived proteins, which means that the cocultures may have diverse combinations of factors 
at different time points based on necessary physiological stimuli. Since Müller cells are also 
known to secrete a variety of factors in response to neuronal damage, they may also have a 
major contribution. In this study, the hNPC feeder layers promoted photoreceptor survival, 
better synaptic integrity and horizontal cell survival. Müller cell gliosis was relieved in the 
form of reduced density of the cells in the cocultures, however, there was no change in GFAP 
protein expression relative to the only cultured explants. The results are discussed below. 
3.4.1 Photoreceptor protection 
In the cocultured retinal explants there was significantly decreased photoreceptor death, as 
indicated by TUNEL+ photoreceptors, relative to the cultured explants. As discussed in the 
earlier sections, photoreceptor death was thought to be related to the deconstruction of the 
OSs due to loss of the RPE. The arrangement of the cone inner and outer segments was better 
maintained in the hNPC cocultures, and although both the experimental groups underwent 
cone OS shortening, the cocultured explants had a significantly higher number of preserved 
OSs. This finding was also paralleled by a significantly lower number of L/M opsin labeled 
cone pedicles in the cocultures. Together, these observations highlight the neuroprotective 
effect of the hNPCs on photoreceptor survival. A means by which this is achieved may be 
related to the hNPCs secreting factors that are similar to those released by the RPE. The RPE 
is known to secrete various diffusible factors that are thought to regulate the transport of 
nutrients and waste products across the retina and also promote photoreceptor functionality 
and homeostasis; these include FGF, TGF-β, IGF-I, PDGF, VEGF, TNF-α (tumor necrosis 
factor – alpha) and members of the interleukin family (259). Since most of these factors were 
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also observed in the hNPC conditioned medium, it could be that the hNPCs share some of the 
functional properties of the RPE to help maintain photoreceptor survival. For instance, in 
detached retinas in vivo it was found that after intravitreal injections with brain-derived 
neurotrophic factor, rod OSs were better preserved and rod opsin redistribution to the plasma 
membrane in the ONL was also reduced (228, 260). A similar scenario may be applicable to 
the cocultures. Another possibility may be that the factors in the hNPC derived medium may 
collectively contribute to the suppression of apoptotic pathways and better regulation of 
intracellular degradation systems. In retinal detachment studies on C57BL mice, IL-6−/− mice 
and Brown Norway rats it was suggested that IL-6 plays an important role in preserving 
photoreceptors through the STAT3 pathway which is predominantly associated with cellular 
proliferation and is considered to be anti-apoptotic (258). In our previous studies, we showed 
that hNPC cocultured rodent explants could help prevent caspase 3, caspase 12 and calpain 
mediated death pathways which may also be applicable in this study (187, 191, 226). 
3.4.2 Synaptic integrity 
The beneficial effects of the hNPCs on photoreceptor survival were also hypothesized to 
result in better maintenance of presynaptic terminals. In the cocultured explants, synaptic 
integrity was demonstrated by a significantly higher number of PNA labeled cone pedicles 
and a significantly lower number of condensed terminals labeled by PSD-95, relative to the 
only cultured explants. Cone pedicles were seen to be subtly labeled by PSD-95 clearly 
showing their triangular morphology. However, although the immunohistochemical studies 
showed better synaptic maintenance, PSD-95 expression levels were similar at the protein 
and genetic levels for both experimental groups. The hNPC culture medium did not seem to 
have much influence on the reduced levels of PSD-95, but possibly helped maintain synaptic 
integrity through other mechanisms. The synaptic terminals are highly complex and consist 
of multiple functional units; further studies are needed to assess whether hNPC protective 
medium target other synaptic proteins. One possible generalized explanation may be that the 
presence of MCP-1 may help synaptic stability; in studies it was found that transgenic mice 
lacking MCP-1 and CX3CR1 developed age-related macular degeneration amongst which 
synaptic pathology was a characteristic phenomenon (256, 261).  
3.4.3 Horizontal cell responses 
Immunohistochemical quantification of calbindin labeled horizontal cells showed a 
significantly higher number of cells in the cocultured explants relative to the only cultured 
counterparts. Although dendritic atrophy was not entirely eliminated, it seemed that the 
dendrites were better maintained in the cocultures. It could be that hNPC culture medium 
may have indirect influence on horizontal cell maintenance through better photoreceptor and 
presynaptic terminal functionality in the 3 div cultures. 
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3.4.4 Müller cell responses 
In the cocultured explants, Müller cell gliosis was attenuated in terms of a significantly 
reduced number of GFAP labeled cells compared to the only cultured explants. Although 
GFAP gene levels were consistent with the immunohistochemical findings, the GFAP protein 
levels were similar for the two experimental groups. These observations may be explained by 
the factors discussed in section 3.3.3.1. Although the results obtained for Müller cell 
responses are inconclusive in this study, it may still be suggested that hNPCs prevent an 
undesired excessive gliotic response. The neurotrophic factors derived from the hNPCs may 
have complex rescue mechanisms; it could be that they mimic the Müller cell/photoreceptor 
intercellular pathway to maintain photoreceptor survival in the cultured explants. It has been 
reported that Müller cells can protect photoreceptor viability through the secretion of a 
number of factors upon exogenous treatment with ciliary neurotrophic factor that binds to its 
cytokine receptor gp130 (262). The degenerating photoreceptors in the explant cultures may 
send rescue signals to the Müller cells to produce neuroprotective factors. As discussed 
before, these factors may initially support photoreceptor survival but with continued gliosis 
could lead to neuronal death. Alternatively, in the hNPC cocultured explants neurotrophic 
factors are secreted by the cells to preserve photoreceptors and this may minimize 
photoreceptor signaling to the Müller cells and thus reduce the gliotic response. Nonetheless, 
based on these findings it is difficult to give a conclusive interpretation of the complex 
interactions of the hNPC and Müller cell derived factors and their implication on 
photoreceptor survival.  
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